key: cord-0978595-a1cibcvu
authors: Beh, Shin C.; Greenberg, Benjamin M.; Frohman, Teresa; Frohman, Elliot M.
title: Transverse Myelitis
date: 2012-11-24
journal: Neurol Clin
DOI: 10.1016/j.ncl.2012.09.008
sha: c957ad83591df265ea6b198f7f4dcdbe7a0f0ec9
doc_id: 978595
cord_uid: a1cibcvu

Transverse myelitis (TM) includes a pathobiologically heterogeneous syndrome characterized by acute or subacute spinal cord dysfunction resulting in paresis, a sensory level, and autonomic (bladder, bowel, and sexual) impairment below the level of the lesion. Etiologies for TM can be broadly classified as parainfectious, paraneoplastic, drug/toxin-induced, systemic autoimmune disorders, and acquired demyelinating diseases. We discuss the clinical evaluation, workup, and acute and long-term management of patients with TM. Additionally, we briefly discuss various disease entities that may cause TM and their salient distinguishing features, as well as disorders that may mimic TM.

does not imply any particular etiology, myelitis refers to an inflammatory disease process.

Transverse myelitis (TM) includes a pathobiologically heterogeneous syndrome characterized by acute or subacute spinal cord dysfunction resulting in paresis, a sensory level, and autonomic (bladder, bowel, and sexual) impairment below the level of the lesion. 2, 3 Etiologies for TM can be broadly classified as parainfectious, paraneoplastic, drug/toxin-induced, systemic autoimmune disorders (SAIDs), and acquired demyelinating diseases like multiple sclerosis (MS) or neuromyelitis optica (NMO). [3] [4] [5] [6] Patients with isolated TM present a diagnostic dilemma, as it is common in both MS and NMO, but may also be the initial manifestation of SAIDs. Also, there are noninflammatory etiologies (eg, vascular, metabolic) that may mimic the clinical and radiologic appearance of TM. Further complicating the diagnostic process is the frequent coexistence of systemic autoantibodies in NMO and, sometimes, MS. The implications of an incorrect diagnosis can be severe, as treatment may not only be ineffective, but may exacerbate the underlying disease process. The cause of TM remains unknown despite an extensive workup in about 15% to 30% 4 of patients and is therefore referred to as "idiopathic" according to set criteria. 7 Box 1 explains important terms related to TM.

The annual incidence of TM ranges from 1.34 to 4.60 cases per million, 8-10 but increases to 24.6 cases per million if acquired demyelinating diseases like MS are included. 11 TM can occur at any age, although a bimodal peak in incidence occurs in the second and fourth decades of life. [8] [9] [10] 12 Half of patients have an antecedent infection. 10 

It is important to consider the age and gender of the patient when evaluating myelopathic patients. Older patients (older than 50 years) are more likely to suffer spinal cord infarction. Female patients are at higher risk of having TM. Demographic features are otherwise not particularly useful in distinguishing the etiologic causes of myelopathy. 13 The temporal profile of the myelopathic features must be elucidated. TM typically has an acute to subacute onset, with neurologic deficits reaching a nadir within a few weeks. An apoplectic onset with deficits reaching the nadir in less than 4 hours indicates a vascular event. An insidious, progressive course in which the deficits continue to worsen beyond 4 weeks is uncharacteristic of TM. Clinically, TM may present as one of several syndromes of the spinal cord. Acute complete TM (ACTM) manifests as paresis/plegia, sensory dysfunction (characterized by numbness, paresthesias, or other manifestations in conjunction with a sensory level), and autonomic impairment below the level of the lesion. Acute partial TM (APTM) results in asymmetric manifestations or deficits specific to particular anatomic tracts; manifestations include the Case report A 30-year-old white woman presents with 3 days of progressive paraparesis, constipation, and urinary incontinence. In addition, she reports a feeling a circumferential tightness around her abdomen (as though she was wearing a corset). Examination revealed spasticity, hyperreflexia with up-going plantar reflexes, and muscle strength of 3 in her lower extremities. Anal tone was decreased. A T8 sensory level was detected. Spine MRI revealed a T2/fluid-attenuated inversion recovery (FLAIR) hyperintense signal with associated contrast enhancement and cord swelling from T2 to 7 vertebral segments. What are the next steps in managing this patient?

hemi-cord (Brown-Sequard), central cord, or posterior column syndrome, as well as selective tract impairment. Table 1 describes these syndromes. Distinguishing ACTM and APTM has etiologic and prognostic significance, as discussed later.

Acutely, limb tone and muscle stretch reflexes may be diminished and even absent ("spinal shock syndrome") leading to possible diagnostic confusion with Guillain-Barre syndrome (GBS). Clinically, spinal shock may persist for days to weeks, with a mean duration of 4 to 6 weeks following an insult. 14 Over time, spasticity, hyper-reflexia, and extensor plantar responses (ie, classic features of the upper motor neuron [UMN] syndrome) become evident.

Sensory symptoms (both positive and negative) are common in TM. Some patients report a circumferential band of dysesthesia, attributable to the dermatomes just rostral to the sensory level, around their trunk. In some cases, this may be associated with a constricting sensation (colloquially referred to as the "MS hug") that ranges from mild discomfort to a severe spasmodic or burning pain. In the authors' experience, this symptom may be so distressing that it may be more appropriately called the "anaconda squeeze"! TM-related pain may be a central, deep aching pain or radicular in nature. 3 Exacerbation of spinal pain with recumbency may indicate a neoplastic lesion involving the spinal cord. 15 Phantom limb phenomenon has been observed. 16 Lhermitte phenomenon (paresthesia traveling down the limbs and trunk with neck flexion) suggests an intrinsic cervical spinal cord lesion, typically affecting the dorsal columns. A reverse Lhermitte phenomenon (paresthesia with neck extension) usually indicates a compressive extra-axial cervical lesion. 17 Inverse Lhermitte phenomenon (paresthesia traveling upward) is another reported variation. 18 Autonomic dysfunction is almost always present in the form of perturbations of bladder, sexual, gastrointestinal, cardiovascular, and thermoregulatory functions. Priapism is a rare acute manifestation. 19, 20 These features are discussed later.

Certain clinical signs can aid in localizing the level of the lesion and are described in Table 2 .

The list of differential diagnoses of TM is long; hence, a meticulous history and detailed physical examination are indispensible. A systematic and careful history may help exclude other mimics of TM (these are discussed in Box 2). An antecedent infection or prior vaccination may implicate acute disseminated encephalomyelitis (ADEM) or parainfectious TM. Travel abroad may indicate more exotic infectious causes of TM, such as schistosomiasis. Risk factors for or concomitant existence of malignancy may implicate a paraneoplastic etiology.

Women of reproductive age are at higher risk of acquired demyelinating diseases and SAIDs with the exception of Behcet disease (BD) and ankylosing spondylitis (AS). A history of relapsing-remitting attacks of neurologic deficits, eg, acute optic neuritis (AON) or internuclear ophthalmoparesis (INO), would suggest MS. Uhthoff phenomenon (discussed later) may be present in demyelinating diseases. A thorough neurologic examination may reveal evidence of prior neurologic impairments suggestive of MS exacerbations disseminated in time and space. NMO usually causes attacks of severe AON (sometimes bilateral) and brainstem lesions resulting in intractable nausea, vomiting, or hiccups. [21] [22] [23] [24] Although the manifestations of NMO may be similar to MS, attacks are typically more devastating. 25 In cases of NMO mistakenly diagnosed as MS, treatment with interferon beta-1a would dramatically increase attacks. 26 Autoimmune disorders, in particular systemic lupus erythematosus (SLE), BD, AS, Sjö gren's syndrome (SS), and antiphospholipid syndrome (APS), are known causes of TM. In some, TM may be the initial clinical manifestation of such a disorder. Fatigue Table 2 Clinical signs with useful localizing value in myelopathic patients

Beevor sign Describes the upward migration of the umbilicus during the act of sitting up from supine position owing to weakness of the lower half of the rectus abdominis (because the upper rectus segments pull in a direction opposite of the lower segments, the movement of the abdomen is upward). In some cases, downward migration of the umbilicus may be observed. This sign indicates a lesion at the level of the T10-12 spinal cord and/or roots. 22 Superficial abdominal reflexes A lesion above T6 segmental cord level will abolish all superficial abdominal reflexes. A lesion at or below T10 spares the upper and middle abdominal reflexes. All the reflexes are present with a lesion below T12. and constitutional complaints are common in patients with autoimmune disorders. A thorough integumentary examination may offer valuable clinical signs. Systemic (eg, renal, cardiac) and nonmyelopathic neurologic manifestations (eg, mononeuritis multiplex, myositis, cerebellar ataxia) may occur in some SAIDs. The presence of peripheral nervous system deficits rules out MS and NMO, unless there are concomitant disorders in the same patient (eg, diabetic peripheral neuropathy). Table 3 describes some salient manifestations of selected systemic autoimmune disorders.

Magnetic resonance imaging (MRI) of the complete spinal axis is mandatory in any patient with myelopathic features to exclude structural lesions, particularly those amenable to emergent neurosurgical intervention. The spinal cord cephalad to the suspected level of the lesion should always be imaged owing to possibly misleading signs, eg, paraparesis attributable to cervical lesions. The most sensitive MRI sequence for detecting spinal cord lesions (especially MS plaques) are short-tau inversion recovery (STIR) fast spin-echo and T2-weighted fast spin-echo sequences. 27, 28 The location and length of the cord lesion on MRI may also provide clues about the underlying disease. Based on clinical and radiologic data, TM can first be dichotomized into longitudinally limited and longitudinally extensive TM (LETM). Longitudinally limited TM can be further classified as ACTM or APTM. ACTM and APTM span 1 or 2 vertebral segments. ACTM causes a complete spinal cord syndrome; on axial sections, there is either full-thickness involvement, or the central portion of the spinal cord is maximally affected. 29 APTM results in asymmetric spinal cord involvement or neurologic deficits attributable to a specific anatomic tract; on axial sections, there is involvement of a portion of the spinal cord. Patients with APTM are at increased risk of recurrence and transition to MS. 13, 29, 30 Conversely, ACTM carries a lower risk of transition to clinically definite multiple sclerosis (CDMS) and is usually related to other causes (eg, SAIDs). LETM refers to lesions that extend over 3 or more vertebral segments; on axial sections, it typically involves more than two-thirds of the spinal cord thickness (maximally affecting the central portion). 3, 29 Box 3 summarizes the differential diagnoses of LETM. The unique radiologic features of different etiologies are explored later. A brain MRI with and without gadolinium administration should also be obtained on all patients to look for evidence of concomitant or prior lesions that may provide clues about the etiology. The presence of MS-like brain lesions in patients with partial TM portends an 80% risk of transition to clinically definite MS at 3 to 5 years. 13 Serum vitamin B12 level, thyroid function tests, syphilis, and HIV serologies always should be obtained to evaluate for potentially treatable causes of myelopathy. Vitamin E, serum copper, and ceruloplasmin levels are checked in those at risk of deficiency (see later in this article for further details). Serum aquaporin-4-specific autoantibodies (NMO-immunoglobulin [Ig]G) should be checked on all patients with TM because of its high specificity for NMO or NMO spectrum disorders (NMOSD). 31,32 NMO-IgG seropositivity is rarely found in patients with APTM 30 but its presence would have profound implications on treatment. Inflammatory markers (please see Box 4) should be checked if SAID is suspected. In suspected parainfectious TM, serologic evidence of recent infection (eg, Mycoplasma antibody titers) should be sought. Serum paraneoplastic profiles should be performed in suspected cases of paraneoplastic TM; additionally, in such cases, appropriate investigations should be undertaken to search for the occult malignancy, the identification of which can have profound ramifications for the patient; even a cure if a malignancy can be confirmed and eradicated before pathologic dissemination.

Cerebrospinal fluid (CSF) analysis is essential in the evaluation of TM. CSF cell count, differential, protein, glucose, oligoclonal bands (OCBs) and IgG index should be checked on all patients with TM. Isoelectric focusing is the superior method for the detection of OCBs, providing a much higher yield and specificity. 33 OCBs are useful in predicting conversion to MS, as OCBs are present in 85% to 90% of patients 13 Bear in mind that their mere presence clearly does not militate against being reflective of a myriad of inflammatory, infectious, and neoplastic or paraneoplastic processes. A neuro-ophthalmological evaluation is warranted to look for ophthalmic manifestations that may provide valuable diagnostic clues, especially when radiologic and laboratory investigations are unremarkable. For example, different subtypes of uveitis are associated with unique etiologic underpinnings. 34 Demyelinating diseases affecting the brainstem and/or cerebellum commonly cause ocular motor manifestations. 35 Electrophysiologic tests may be very useful in assessing patients with TM. Nerve conduction studies and electromyography (EMG) may reveal and help characterize any peripheral nervous pathology, the exclusion of which would lend compelling support for a spinal cord process. This latter principle is especially salient in that acute TM can present as a spinal shock variant, one that may mimic a polyneuropathic process like GBS. In early TM, F-waves may be absent, 36 an observation that can serve to misguide even the most experienced neurologic consultant (especially when the MRI is unremarkable) to localize the disease process to the peripheral nervous system. EMG-evidence of anterior horn cell dysfunction may portend a poor prognosis for recovery. 37 Somatosensory evoked potentials may offer evidence of a myelopathy in the presence of a normal spinal cord MRI. In addition, conventional and multifocal visual-evoked potentials (VEP) may provide evidence of subclinical demyelination along the afferent visual pathways not clearly identified on imaging. Evidence of such disruption may support the diagnosis of MS or NMO but are by no means specific for these disease entities (discussed in greater detail later).

A list of investigations into TM is provided in Box 4.

Box 5 summarizes the causes of TM.

MS is a disabling progressive neurologic disorder affecting approximately 400,000 people in the United States. 38 First attacks of MS, called clinically isolated syndrome (CIS), usually consist of AON, brainstem syndromes, or APTM. The probability for APTM to transition to CDMS ranges from 10% to 62%. 30,39-43 APTM may be a CIS with a higher risk of conversion to MS. 43 TM in MS most commonly presents with sensory phenomena. Spine MRI typically reveals an asymmetrically placed lesion (usually occurring in the posterolateral or lateral portion of the spinal cord) less than 2 segments in length (ie, APTM) with a predilection for the cervicothoracic cord. 3, 30, 39, 42, 43 The most important investigation that helps determine the risk of conversion to CDMS is the brain MRI. If it is normal, only 10% of patients with APTM will develop CDMS at 61 months 30 ; this increases to 21% risk of progression at 20 years followup according to another study of CIS. 44 White matter lesions predict higher risk of conversion to MS (with rates of up to 88% reported). 43, 44 If the lesions meet at least 3 of the Barkhof criteria 45 this risk is increased substantially. 43 Another important factor that helps predict the risk of transition to CDMS is CSF OCBs. In the setting of TM, OCBs have been shown to have a robust predictive value of for predicting conversion to MS. 43, [46] [47] [48] In patients with TM with normal brain MRIs, the presence of OCBs and/or an elevated IgG index portends a higher risk of developing MS. 49 The risk of developing MS is less than 10% with a normal brain MRI and CSF findings. 43 Longitudinally extensive lesions in the context of TM is actually quite rare in MS and, when present, is significantly shorter than those seen in NMO. When MS is confirmed, spinal lesions tend to favor a cervical localization, and tend to have less cord swelling and gadolinium-enhancement. 50 In general, patients with LETM have been shown to have a conspicuously low risk of developing MS. 30 

NMO is diagnosed on the basis of the revised Wingerchuk criteria 51 requiring the presence of optic neuritis and TM as well as 2 of 3 of the following: NMO antibodies, LETM, and/or brain MRI lesions inconsistent with MS. NMOSDs include Asian optic-spinal MS, recurrent LETM, recurrent AON, and AON or TM in the context of certain organ-specific and non-organ-specific autoimmune disease. The article on NMO by Sahraian, MA, elsewhere in this issue discusses this disease in detail. Here, we underscore the important features of NMO that give rise to diagnostic confusion.

Diagnostic confusion may arise with SAIDs, as patients with NMO/NMOSD often have accompanying autoimmune diseases and multiple non-organ-specific autoantibodies. Autoimmune diseases observed to coexist with NMO include SS, SLE, autoimmune thyroid disease, type 1 diabetes mellitus, ulcerative colitis, idiopathic thrombocytopenic purpura, myasthenia gravis, rheumatoid arthritis, polymyositis, celiac disease, and Raynaud phenomenon. 52, 53 We propose that all patients with a known SAID (eg, SS or SLE) who present with TM undergo serologic testing for NMO-IgG. The high specificity of NMO-IgG seropositivity 31,54 will establish the additional diagnosis of NMO coexisting with the systemic autoimmune disorder. In patients with NMO or TM, the isolated presence of systemic non-organ-specific antibodies should not be used to make a diagnosis of any particular rheumatic disease; instead, these assays can lend support in corroborating such conditions, when the established clinical criteria for each respective disorder has been fulfilled.

SS is a chronic, protean, progressive, systemic autoimmune disorder characterized by mononuclear infiltration and destruction of the salivary and lacrimal glands, leading to keratoconjunctivitis sicca, typically affecting middle-aged to elderly women. SS may appear alone (primary SS) or exist with another autoimmune disease (secondary SS). [55] [56] [57] A wide range of central nervous system (CNS) manifestations may occur, including AON and TM. 56, 58, 59 The precise prevalence of neurologic manifestations in SS is unclear, and has been reported to range from 8.5% to 70.0% 57 ; this large discrepancy may be related to the inclusion or exclusion of psychiatric and cognitive impairment. Neurologic deficits may be the initial presentation in as many as 57% of patients with SS. 57 Spinal cord involvement (either acute TM or progressive myelopathy) may occur in 20% to 35% of patients with SS and may constitute the initial presentation of the disease in up to about 20%. 55, 57 The lesions tend to affect the cervical cord and may be longitudinally extensive. 57, 60 CSF typically reveals pleocytosis, mildly increased protein, and a mildly elevated IgG index. 56, 60 Cytologic analysis may reveal small round lymphocytes, reactive lymphoid cells, plasma cells, and atypical mononuclear cells. 56 OCBs have been reported in about 30% of patients with SS. 57 SS-A or SS-B antibody seropositivity is not mandatory for the diagnosis of SS, because only 21% of patients with primary SS and neurologic manifestations demonstrate such seropositivity. 57 Although other CNS manifestations of SS are corticosteroid-responsive, 56 spinal cord involvement is often refractory to steroids. 60 Intravenous (IV) cyclophosphamide is effective 56, 57 ; there is anecdotal evidence supporting the use of plasmapheresis 61 and IV gammaglobulin. 62 Maintenance immunosuppressive therapy with monthly pulse IV cyclophosphamide may be considered. 56 Rituximab is another promising agent 63 and may be a suitable agent for patients with coexisting NMO or MS, or where there is diagnostic confusion with these diseases. Careful longitudinal follow-up is important in SS, as recurrent attacks of TM or AON can culminate in substantial disability, and may ultimately lead to a confirmed diagnosis of NMO or MS.

SLE is a chronic, systemic, autoimmune disease. The diagnosis of SLE requires at least 4 of 11 features, as outlined by the American College of Rheumatology. 64 Although neuropsychiatric manifestations of SLE are common, TM accounts for only 1% to 2% of patients, 65 but constitutes the most devastating complication of SLE and one that often portends a poor prognosis. 66 SLE-related TM tends to occur within the first 5 years from diagnosis, is the initial clinical manifestation in almost half of patients, and recurs in 21% to 55% of cases. [67] [68] [69] AON and brainstem manifestations may accompany TM in SLE, 70, 71 mimicking MS and representing a significant source of diagnostic confusion.

A short period of prodromal symptoms (eg, headache, fever, nausea) typically heralds the onset of thoracic myelopathy with prominent bladder dysfunction. 69, 71 In a large series of SLE-related TM, 2 different clinical patterns at presentation were observed: gray and white matter myelitis. Gray matter myelitis demonstrated lower motor neuron (LMN) features, urinary retention, and a more devastating but monophasic course. White matter myelitis demonstrated UMN features and a more indolent but recurrent course. 72 An earlier study suggested that EMG evidence of anterior horn cell dysfunction in patients with TM predicts a poor prognosis for recovery. 37 The features of gray and white matter myelitis are summarized in Table 4 .

Although low-titer positive antinuclear antibodies (ANA) in idiopathic TM (ITM) cases are similar to that of the general population, much higher serum ANA titers, antidouble-stranded DNA antibodies, and hypocomplementemia are found in SLErelated TM. 68, 71 The presence of antiphospholipid antibodies (APLA) in SLE has been suggested to increase the risk of developing TM 73 but this association has been challenged. 67,69 CSF pleocytosis with elevated protein and intrathecal IgG synthesis are typically detected, particularly in LETM 68, 69, 71, 74 ; interestingly, OCBs, although unusual, have been observed in APLA-seropositive patients. 69 The most common MRI finding in SLE-related TM is a longitudinally extensive, T2-hyperintense lesion (accompanied by cord swelling). 68, 69, 71, [74] [75] [76] [77] [78] In severe cases, the lesion involves the entire spinal cord and extends into the medulla. 79,80 Radiologic findings may not correlate with the clinical course. 68 Almost a third of patients with SLE-related TM do not have any detectable MRI abnormalities at presentation. 67 On brain MRI, subcortical lesions predominate in APS and SLE, whereas periventricular and callosal lesions are more common in MS. 81 In a randomized controlled trial, IV cyclophosphamide was found to be more efficacious in treating neuropsychiatric manifestations of SLE compared with IV methylprednisolone. 82 The combination of high-dose IV methylprednisolone and IV cyclophosphamide may be effective in SLE-related TM if instituted promptly, resulting in improvement in a few days to 3 weeks. 67, 70, 83, 84 Relapses are common (50%-60%) during corticosteroid dose taper, emphasizing the need for maintenance immunosuppression. 70 Plasmapheresis has been used in severe cases. 67, 71, 85, 86 There is anecdotal evidence for using intravenous immunoglobulin and rituximab. 71, 87, 88 Anticoagulation therapy is indicated only in those with a history of thrombotic phenomena. 69, 71, 73, 74 Long-term aspirin use has anecdotal support. 74 Factors associated with severe neurologic deficits include extensive cord MRI lesions, LMN features and sphincteric dysfunction at onset, APLA, and delayed (>2 weeks) initiation of therapy. 67, 72, 89 Antiphospholipid Syndrome APS is a systemic, autoimmune disorder characterized by recurrent thrombotic events and/or miscarriages, as well as APLA seropositivity (2 or more occasions at least 6 weeks apart) (ie, anticardiolipin, lupus anticoagulant, and anti-beta-2-glycoprotein I antibodies). 90 In secondary APS, the disease coexists with another autoimmune disorder.

TM is an unusual complication of APS, with a prevalence of less than 1%. [91] [92] [93] Although typically monophasic, recurrent corticosteroid-responsive LETM has also been observed. 92 Characteristically, acute thoracic cord dysfunction occurs with sphincter involvement. 93 Spine MRI may be normal on presentation in up to 40% of patients, underscoring the importance of repeat imaging in suspected cases. 94 It is hypothesized that interactions between APLA and spinal cord phospholipids are responsible for APS-related TM, 95 explaining the efficacy of and justifying the use of early high-dose corticosteroid therapy. 93 In corticosteroid-refractory patients, cyclophosphamide, plasmapheresis, and rituximab may be needed. 93 A higher prevalence of APLA seropositivity has been reported in patients with MS and appears to rise with disease duration. [96] [97] [98] [99] [100] Although diagnostic confusion may arise in APLA-positive patients with TM, the presence of CSF OCBs and the absence of prior miscarriages or thrombotic phenomena would favor MS rather than APS.

BD is a relapsing multisystem inflammatory disorder of unclear etiology resulting in oral aphthous ulcers, genital ulcers, uveitis, cutaneous manifestations, and involvement of other organ systems. 101 Neurologic involvement in BD (neuro-BD) may follow or precede the onset of systemic manifestations. 102 Neuro-BD typically occurs in the third to fourth decade of life, is more common in men, and is usually associated with ocular involvement. [102] [103] [104] The frequency of neuro-BD varies greatly, from 1.3% to 59.0%, with a pooled average of 9.4%. 102, 104 Neuro-BD can be classified as parenchymal or nonparenchymal (vascular). Parenchymal neuro-BD commonly manifests as a meningoencephalitic syndrome with headaches and focal neurologic deficits. 102 The manifestations of vascular BD stem from cerebral venous thrombosis (often with subsequent increased intracranial hypertension) and/or rarely, arterial infarctions. 105 Spinal cord involvement ranges between 2.5% and 30.0%, with a predilection for the cervical and thoracic cord segments (in particular the posterolateral cord), and carries a poor prognosis. 102, 103, [106] [107] [108] [109] Isolated TM in neuro-BD is distinctly unusual. 102, 105 Spinal cord lesions are usually longitudinally extensive and involve multiple noncontiguous segments, or even involve the entire cord. Cord swelling and T2-hyperintense, nonenhancing lesions are present in the acute or subacute phase. 106, 107, [109] [110] [111] [112] [113] [114] An unusual report of TM (extending from T9 to the conus) following CT-guided L2 nerve root injection, may be a florid demonstration of the pathergic reaction in the spinal cord. 115 Brain MRI may reveal T1-hypo/isointense and T2-hyperintense lesions that may or may not show gadolinium enhancement acutely. Characteristically, an upper pontomesencephalic lesion with thalamic, hypothalamic, and basal ganglial extension on one side is seen. 102, 105, 107, 109, 116, 117 Interestingly, the red nucleus is almost always spared. 107, 109 Striking brainstem atrophy, as well as the rarity of periventricular lesions, optic neuropathy, cortical atrophy, and gray matter lesions in neuro-BD, 102, 109, 117, 118 distinguish it from MS.

CSF typically reveals normal glucose, increased protein, and neutrophilic pleocytosis; the IgG index may be elevated, and OCBs are rare. [103] [104] [105] [106] 108, 117 Acutely, administration of high-dose corticosteroids results in improvement in most patients 103, 104, 108, 110, 111, 113, 119 ; corticosteroid therapy also improved pleocytosis. 117 Infliximab, cyclophosphamide, and intravenous immunoglobulin have been used with some success. 104, 120 No randomized controlled trials have been conducted into the treatment of neuro-BD. Azathioprine, mycophenolate mofetil, and methotrexate have been used as initial immunosuppressive therapy. In more aggressive disease, tumor necrosis factorantagonists or monthly infusions of cyclophosphamide have been used. Colchicine, thalidomide, and pentoxifylline may be used for mucocutaneous lesions. [102] [103] [104] Cyclosporin A has been used to treat ophthalmic manifestations but may be neurotoxic and worsen neurologic manifestations. [121] [122] [123] [124] TM in Other Rheumatologic Diseases TM has been reported in AS, psoriatic arthritis, mixed connective tissue disease, and systemic sclerosis (please refer to Table 5 ).

Sarcoidosis is a multisystem granulomatous disease with protean manifestations that may affect any organ. Neurologic involvement (neurosarcoidosis) is reported in 5% to 13% of patients with sarcoidosis 125-128 but may be as high as 26%. 129 The usual age of onset is the fourth decade. 127, 130 Spinal cord neurosarcoidosis appears to be more common in men. 131, 132 CNS features are the initial manifestation of neurosarcoidosis in up to 70% of patients. 130 Although unusual, spinal cord involvement portends a poor outcome, and may be related to intramedullary, intradural extramedullary, or extradural lesions; cauda equina syndrome; or arachnoiditis. 130, 131, 133 Although isolated myelopathy has been observed, half of patients with spinal cord neurosarcoidosis demonstrate systemic manifestations. 129, 133, 134 Neurosarcoidosis has a predilection for the cervical and thoracic cord 131,132,135-137 and is frequently associated with back pain and radicular symptoms. 131,138-140 Table 5 Other dysimmune disorders associated with TM

Ankylosing spondylitis Neurologic involvement is rare and is almost always attributable to compressive myelopathy. Noncompressive myelopathy is exceptionally rare with only 2 clearly documented cases of TM. [368] [369] [370] Psoriatic arthritis 371 Mixed connective tissue disease Female preponderance; predilection for the thoracic cord. [372] [373] [374] [375] [376] [377] Systemic sclerosis Rare and typically compressive in etiology. Progressive myelopathy, subacute TM, and NMO-IgG positive LETM have been reported. [378] [379] [380] [381] Anti-Jo-1 antibody A single report of TM preceding the development of polymyositis and pulmonary fibrosis in a patient with anti-Jo-1 antibody. 382 Urticarial vasculitis Urticarial vasculitis may be primary disorder or coexist with other autoimmune diseases. 383 pANCA seropositivity Perinuclear antineutrophil cytoplasmic antibody (pANCA) seropositivity has been reported to cause TM associated with CSF pleocytosis and increased protein with typically absent OCBs. 384, 385 Celiac disease Celiac disease is an immune-mediated disorder characterized by intolerance to dietary gluten. 386 Thymic follicular hyperplasia Recurrent multifocal TM associated with thymic follicular hyperplasia that resolved following thymectomy. 387 Graft-vs-host disease TM may be a rare manifestation of graft-vs-host disease following hematopoietic cell transplantation. [388] [389] [390] Common variable immunodeficiency A primary immune deficiency disorder characterized by hypogammaglobulinemia, antibody deficiency, and recurrent infections. 391, 392 Abbreviations: CSF, cerebrospinal fluid; LETM, longitudinally extensive transverse myelitis; NMO-IgG, aquaporin-4-antibody; OCB, oligoclonal bands; SLE, systemic lupus erythematosus.

Intramedullary disease typically appears as a longitudinally extensive, T1hypointense, T2-hyperintense, heterogeneously enhancing lesion with fusiform cord enlargement or myelomalacia. 131, 141 Spinal cord lesions may be multifocal; gadolinium enhancement may be nodular or predominate at the periphery of the lesion. 129, 131, 132 Neurosarcoidosis should be suspected in any infiltrating intramedullary cord lesion with leptomeningeal enhancement. Half of patients with spinal neurosarcoidosis have concomitant intracranial lesions. 131, 141 The diagnosis of spinal cord neurosarcoidosis is challenging, particularly if systemic manifestations are absent. When clinical suspicion is high, even in the absence of systemic symptoms, it is worthwhile performing a high-resolution chest CT, positron emission tomography, ophthalmic examination, or a gallium-67 scan to identify extraneural granulomas that may be amenable to biopsy. 66, 140, 142 CSF findings reveal elevated protein, lymphocytic pleocytosis, occasional hypoglycorrachia, and infrequent OCBs. CSF angiotensin-converting enzyme levels are normal in more than half of patients. Hypoglycorrachia is specific and can distinguish neurosarcoidosis from other inflammatory etiologies. 130, 131, 140, 143 Early corticosteroid therapy results in remarkable recovery but delayed treatment leads to only partial resolution of myelopathic manifestations. 132 A high index of suspicion for the diagnosis is required because early intervention is associated with a favorable outcome.

Vogt-Koyanagi-Harada syndrome (VKH), also known as uveomeningoencephalitis, is a systemic inflammatory disorder affecting the melanin-forming cells in different organs. 144 TM is an infrequent complication of VKH, 145, 146 and bilateral AON with papilitis has been reported. 147 These manifestations may mimic MS or NMO. CSF pleocytosis can provide early evidence of disease activity, therefore allowing early treatment with corticosteroids. 148, 149 Acute Disseminated Encephalomyelitis ADEM is a monophasic disorder that occurs following infections or vaccinations, is associated with multifocal demyelinating lesions, and may include encephalopathy, coma, and/or seizures. 150 TM occurs in about 24% of patients 151 and, in unusual cases, may be the sole manifestation of ADEM. 152 It is possible that some cases of TM represent limited forms of ADEM. 29 Unlike MS and NMO, ADEM may be associated with demyelinating peripheral neuropathies. 153 ADEM may occur at any age but is most common in the pediatric population (mean age of onset of 5.7 years). 154 Postvaccination ADEM incidence is variable, and the most frequently implicated vaccine is the non-neural measles, mumps, and rubella vaccine. 66, 155 An initial attack consistent with a demyelinating event with acute or subacute onset, a stable to stuttering course (evolving over 1 week to 3 months), characteristic MRI features, and concomitant encephalopathy and meningismus, suggests a diagnosis of ADEM. 66 Radiologically, acute, multiple, symmetric, supratentorial and infratentorial lesions, with one at least 1 cm in diameter are observed; symmetric basal ganglial and thalamic involvement is common. 66, 151 The lesions should be of the same age and demonstrate homogeneous gadolinium enhancement, as ADEM is typically monophasic. 156, 157 The typical spinal cord lesion is swollen, enhances variably, and predominantly affects the thoracic cord. 151 It may take up to 14 days from the onset of symptoms for the MRI to show abnormalities. 158 CSF in ADEM typically reveals marked pleocytosis, elevated protein, normal IgG index, and no OCBs. 155, 159, 160 Treatment with high-dose IV corticosteroid therapy may help diminish inflammation and restore the blood-brain barrier integrity. Early initiation of plasmapheresis (within 15 days of onset) has been shown to result in clinical improvement and should be offered to those who fail steroid therapy. [161] [162] [163] [164] [165] Parainfectious TM Parainfectious TM (PITM) refers to TM associated with an antecedent infection. It is unclear if it shares the same pathophysiological underpinnings as ADEM (and represents different ends of a spectrum) or if they are separate entities. Both are preceded by typically monophasic, steroid-responsive events preceded by infections. It is difficult to determine if PITM is caused by direct microbial invasion (causing myelitis by either the direct pathogenic destruction, or from the pathogen-triggered immune reaction), or a consequence of immune-mediated, inflammatory mechanisms induced by a remote infection. The antecedent infection has typically resolved before the onset of TM and it is difficult to demonstrate the offending organism in the spinal cord parenchyma.

The hepatitis viruses may cause TM via postinfectious, immune-mediated, inflammatory mechanisms. 166 Hepatitis A virus and Hepatitis B virus infection have been associated with immune-mediated TM. 166 Hepatitis C virus (HCV) is the most commonly implicated hepatitis virus in TM. HCV has been associated with recurrent, corticosteroid-responsive, demyelinating TM (even without hepatic involvement). [166] [167] [168] [169] [170] [171] There is a single report of hepatitis E-virus associated TM. 172 Viruses associated with PITM 155,173-186 are listed in Box 5. CNS manifestations are the most common extrapulmonary complication of Mycoplasma pneumoniae infection. 155, [187] [188] [189] Although encephalitis is the most frequent complication, 189 TM is the most severe and debilitating manifestation. 190 Acute to subacute thoracic myelopathy typically arise 2 to 4 weeks after the antecedent respiratory infection and progress to a nadir in about 3 days; it may be accompanied by meningoencephalitis and/or polyradiculopathy. 190 LETM has been reported. [191] [192] [193] A predominantly mononuclear pleocytosis with increased protein and normal glucose levels are frequently found. 190 Serologic detection of anti-Mycoplasma antibodies supports the diagnosis. Positive M pneumoniae CSF polymerase chain reaction provides reliable diagnostic evidence of preceding infection.

Antecedent Campylobacter jejuni infection has been classically associated with GBS, presumably because of molecular mimicry between bacterial lipopolysaccharides and human gangliosides. It has been associated with TM, [194] [195] [196] [197] [198] [199] and 1 case of biopsy-proven CNS vasculitis. 200 In patients with TM with a recent diarrheal illness, stool cultures for C jejuni and serologic studies for antiganglioside antibodies should be considered.

Bacteria reported to cause PITM 155, 195, [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] are listed in Box 5.

Fungal and parasitic causes of PITM 5,215-223 are rare; these are listed in Box 5. These microbes most likely cause myelopathy by direct pathogenic effects. One noteworthy parasite is the pinworm (Enterobius vermicularis), which has been reported to cause TM associated with anti-GM1 antibodies (which are also seen in C jejuni infection) via molecular mimicry. 224 Pathogens associated with parainfectious LETM [167] [168] [169] [170] 186, 192, 193, 201, 209, 212, 213, [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] are listed in Box 3.

It is imperative to remember that the occurrence of TM following an infection does not automatically implicate ADEM or a parainfectious autoimmune response. Longitudinal follow-up is needed and further evaluation may be warranted because infections may trigger TM that heralds the diagnosis MS or NMO. Diagnostic confusion may arise in cases in which concomitant parainfectious AON 240, 241 and TM may mimic the appearance of a demyelinating disease. As such, longitudinal follow-up is required to ascertain the nature of the disease.

Collapsin response-mediator protein-5 (CRMP-5-IgG) antibodies, observed in smallcell lung cancer, is the paraneoplastic antibody most commonly associated with TM; LETM has also been observed. CRMP-5-IgG-related AON is a recognized manifestation of this paraneoplastic syndrome. A clinical picture resembling MS or NMO may arise. 242, 243 Patients demonstrate a subacute, progressive, predominantly motor myelopathy as well as increased CSF protein, elevated IgG index, and mild pleocytosis. 242, 244 MRI demonstrates T2-hyperintense lesions with occasional gadolinium enhancement. In more than 40% of patients, LETM may be demonstrated. 242 Other paraneoplastic antibodies associated with TM are listed in Table 6 .

Atopic myelitis (AM) demonstrates a chronic persistent or fluctuating course of predominantly cervical myelitis, associated with marked hyper-IgEemia, allergenspecific IgE (most commonly to dust mites), and occasional coexistent atopic diseases (eg, atopic dermatitis, atopic rhinitis, asthma). 245 The vast majority of reported cases occur in Japanese patients, but a there are a few reports of AM in White patients. 246, 247 Sensory deficits are the predominant symptom, with infrequent motor and bladder involvement. 248 On MRI, the lesions are T2-hyperintense with variable gadolinium enhancement, appear to favor the posterior columns of the cervical cord, and are limited to 1 to 2 vertebral bodies. 248, 249 Because the clinical and radiologic picture resembles MS, it is imperative to obtain a brain MRI to look for lesions that would be suggestive of MS. 250 CSF cell count and protein are typically normal and OCBs are not seen. 249, 250 VEP may be abnormal in more than 20% of patients with AM (and therefore may not help distinguish it from MS), as atopic AON has been reported to occur as well. 250, 251 TM in Other Dysimmune Disorders Table 5 lists various dysimmune disorders that have been associated with TM. Table 6 Paraneoplastic antibodies associated with TM aside from collapsin response-mediator protein 5 Ig antibodies

Anti-Ri (ANNA-2) Anti-Ri antibodies are usually associated with lung or breast carcinoma 393, 394 Anti-amphiphysin IgG Classically associated with breast cancer and stiff man syndrome 395, 396 Anti-glutamic acid decarboxylase (GAD65)

Classically associated with stiff person syndrome, cerebellar ataxia, diabetes mellitus type 1, and limbic encephalitis 244, 397 N-methyl-d-aspartate receptor (NMDAR)

Classically associated with limbic encephalitis, and related to ovarian teratomas.

Drug-induced and Toxin-related TM Drugs and toxins associated with TM are listed in Table 7 .

The Transverse Myelitis Consortium Working Group has proposed a set of strict criteria for the diagnosis of ITM, 7 which are summarized in Table 8 . To make the diagnosis, all inclusion and no exclusion criteria should be present. The application of these criteria has resulted in a fairly homogeneous group of patients in terms of clinical and radiologic data. 252 The reported proportion of patients with TM with ITM varies widely, from 16% 252 to approximately 60%. 253, 254 The overall mean age of disease onset appears to be between 35 and 40 years, with a female preponderance. 252, 254 The MRI typically demonstrates a centromedullary lesion, extending over 2 vertebral segments and involving more than two-thirds of the cross-sectional area of the spinal cord, with a predilection for the thoracic cord. 41, 252, 253, [255] [256] [257] [258] [259] Cord swelling is seen in half of cases. Gadolinium enhancement (which may be nodular, peripheral, heterogeneous, or moderately diffuse) occurs in approximately one-third to one-half of cases. 41, 252, 253, 255 CSF shows increased protein in most patients; pleocytosis and OCBs are sometimes seen. 41, 252, 258 Interestingly, unlike other causes of TM, negative OCBs is correlated with recurrence. 252 ITM is typically monophasic but recurs in about one-quarter to one-third of cases (recurrence of initial insult, expansion of prior lesion, or a new lesion). 8, 12, 66, 252, 259 Risk factors for recurrence seem to be the following: (1) male gender; (2) age older than 50 years; (3) severe motor weakness and sphincteric dysfunction; and (4) negative CSF OCBs, normal IgG index, and NMO-IgG seronegativity. 252, 258, 259 Recurrences are associated with a poor outcome. 259 Interestingly, Kim and colleagues 258 and Alvarenga and colleagues 254 both reported recurrences exceeding 60% in their respective studies despite the low rate of NMO-IgG seropositivity. There are several serologic, CSF, and radiologic differences among the patients with recurrent ITM in these studies and may represent distinct clinical entities that have yet to be characterized. A Korean study of 15 patients with recurrent ITM lends support to the hypothesis that recurrent ITM may represent a unique entity. 260 More longitudinal studies are needed to clearly elucidate the characteristics of recurrent ITM. Chemotherapeutic agents Gemcitabine, cytarabine (cytosine arabinoside), and cisplatin. [404] [405] [406] [407] [408] General and epidural anesthesia

The association between TM and general anesthesia is debatable. [409] [410] [411] [412] [413] [414] [415] Heroin Although most of cases of myelopathy in heroin addicts result from anterior spinal artery infarction, there are reports of TM.

Benzene 420 Brown recluse spider bite Incomplete TM (anterior spinal syndrome), responsive to corticosteroid therapy. 421 Abbreviations: CNS, central nervous system; TM, transverse myelitis; TNF, tumor necrosis factor.

The response of ITM to corticosteroid therapy is usually disappointing. 41, 252 In general, one-third of patients with idiopathic acute transverse myelitis recover with little or no sequelae, one-third are left with a moderate degree of permanent disability, and one-third have severe disabilities. 252 Spinal shock at presentation was highly predictive of a poor outcome. 252 Interestingly, a higher CSF glucose level (related to higher serum levels) may portend a poorer outcome. 41 

On the whole, the incidence of TM in children is much lower than that of the adult population. There appears to a bimodal distribution: toddlers younger than age 3, and children between 5 and 17 years. Males and females are equally affected. Antecedent infections (typically respiratory) or preceding vaccinations are common. 10, 261, 262 Because of the association with respiratory infections, there is a clustering of TM cases in the winter months. 262, 263 Compared with adults, pediatric TM is more frequently postinfectious, thoracic, centromedullary, and longitudinally extensive. The risk of conversion to MS is lower and functional recovery is often better than in the adult population. [261] [262] [263] [264] [265] [266] Complete recovery appears to be the rule with poor outcome in only a minority of patients. 264, 266, 267 The course in pediatric TM has been divided into 3 phases: onset, plateau, and recovery. The plateau may last up to 4 weeks; if recovery has not started by the end of this period, the likelihood of recovery diminishes. 262, 264, 268 Beyond 6 months, any improvement is very improbable. 264 CSF analysis frequently reveals pleocytosis and elevated protein; OCBs and increased IgG indices are rare. 261, 262, 264 Although the proportion of pediatric TM cases with LETM is higher than that of adults, the rate of NMO-IgG seropositivity is much lower. 262, 269 This low rate of NMO-IgG seropositivity, with the typically monophasic clinical course and benign outcome in pediatric LETM, suggests that the pathobiological underpinnings of LETM in the pediatric population is different from that in adults. Age younger than 3 years, requirement for respiratory support, severe impairment at onset, flaccid paralysis at onset, a more rapid progression to the nadir of weakness, CSF pleocytosis, and MRI T1-hypointensity at the time of diagnosis were poor prognostic indicators for recovery. 261, 264, 267, 268 Early treatment with IV methylprednisolone had a significant positive effect on outcome. 264 The most common long-term neurologic complication of TM in children is bladder dysfunction. 261, 264, 266 As in adults, APTM, CSF OCBs, and the brain MRI lesions portend an increased risk for transition to MS; LETM carries a low risk of developing MS. 262 Table 9 highlights the important CSF and MRI features of the different causes of TM.

Pseudoexacerbation is a phenomenon in which patients experience temporary worsening of previously suffered neurologic deficits. In demyelinating disorders, Uhthoff phenomenon is the most common underlying cause of pseudoexacerbation (authors' personal experience). Any condition that increases the patient's body temperature (eg, febrile illness, exercise, hot weather, hot baths, hot showers, stress, menses, dehydration) can cause a pseudoexacerbation. Any infection, particularly urinary tract infections (UTI) may result in pseudoexacerbation. In fact, any metabolic or physiologic derangements (eg, hyperglycemia, hypertension) has the potential to transiently worsen prior neurologic deficits. In conclusion, worsening of prior myelopathic symptoms in a patient with previous TM does not automatically implicate a recurrence or relapse. Pseudoexacerbation should be considered and investigations into the cause of pseudoexacerbation should be undertaken. Treatment of recurrent TM entails immunosuppressive therapy, but treatment of pseudoexacerbation involves addressing the underlying cause (eg, treating the UTI).

In making the diagnosis of TM, it is essential to remember that many noninflammatory etiologies may mimic the appearance of TM. Recognizing these entities is important, as the treatment and management strategies would be vastly different. Entities important to recognize include vascular myelopathy, compressive myelopathy, metabolic/toxic myelopathy, neoplasms, and radiation myelitis. Selected etiologies are described in Table 10 .

Once the diagnosis of TM is made, immunotherapy should be instituted to stop the inflammatory process and therefore allow recovery to commence. In a small openlabel trial, high-dose IV methylprednisolone was shown to improve the outcome in pediatric TM. 264 Despite the lack of randomized controlled studies, administration of high-dose IV corticosteroids (IV methylprednisolone 1 g daily for 3-7 days) should be started as early as possible in all patients with TM. 13 In patients with poor or no response to corticosteroids, plasmapheresis should be offered, 13 with the rationale of removing humoral factors inciting TM. The benefits of plasmapheresis have been proven in acute attacks of CNS demyelinating diseases. [163] [164] [165] 270 Early initiation of plasmapheresis (within 15 days of onset) is the best predictor of a favorable acute response and of improvement at 6 months. 164, 165 The typical regimen is exchanges of 1.5 plasma volumes for 5 treatments over 10 days. 271 Plasmapheresis also has anecdotal support in various systemic autoimmune disorders (described previously). Although plasmapheresis may provide benefit beyond that obtained with steroids, patients with American Spinal Injury Association (ASIA) A level of disability may need IV cyclophosphamide as well. 272 IV cyclophosphamide appears to be efficacious in active inflammatory MS 273, 274 and other autoimmune conditions. The major concern with cyclophosphamide is the adverse effect profile, which includes nausea, hemorrhagic cystitis, and malignancies.

In high cervical cord lesions extending into the medulla, respiratory failure may be fatal 275 ; therefore, in such patients, vital signs and respiratory function should be vigilantly monitored. Other acute issues that may arise include immobility (and the complications thereof), urinary retention, constipation, and gastroparesis. These are discussed later in this article.

In cases of TM attributable to systemic autoimmune disease or acquired demyelinating disease, commencement of long-term immunomodulatory therapies would help prevent future attacks. 3 A discussion of these therapies is beyond the scope of this article.

A very important aspect of managing TM focuses on the multiple complications arising from the disease. The main thrust of long-term management is neurorehabilitation, the active process by which those disabled by injury or disease achieve a full recovery or, if full recovery is not possible, realize their optimal physical, mental, and social potential and are integrated into their most appropriate environment. 276 Successful neurorehabilitation is dependent on a multidisciplinary assessment that can develop goal-oriented programs tailored for the patient's specific needs; therefore, early consultation with the physical medicine and rehabilitation physician, physical therapist, occupational therapist, and psychologist/psychiatrist is vital. In fact, there is evidence that a multidisciplinary comprehensive care center is a highly efficient and cost-effective care delivery system that minimizes adverse events, lowers rehospitalization rate, and improves patients' perception. 277 Mobility and Gait Impairment

In the acute phase of TM, weakness may be severe and care should be taken to avoid the complications of prolonged immobility. Low molecular weight heparin or Vitamin B12 deficiency May present as an isolated myelopathy or in combination with neuropathy, encephalopathy, and/or behavioral changes. Dorsal column impairment is the most common manifestation, followed by pyramidal dysfunction (the classic subacute combined degeneration of the cord). Hematologic manifestations may be absent up to 30% of patients with neurologic manifestations. MRI reveals T2-hyperintense signal in the posterior columns (the "inverted V" or "inverted rabbit ear" sign on axial views). In severe cases, MRI shows the "anchor" sign (because of involvement of the posterior, anterior, and pyramidal tracts). [422] [423] [424] [425] Vitamin E deficiency May cause a predominantly dorsal column syndrome associated with a peripheral neuropathy because of axonal degeneration. Preferentially affects the cervical cord. Clinically and radiologically similar to B12 deficiency. [426] [427] [428] Copper deficiency May cause both myelopathy and optic neuropathy. Causes of acquired copper deficiency include malnutrition, zinc toxicity, Menke disease, bariatric surgery, gastrectomy, malabsorption syndromes, and use of copper chelating agents. Clinically and radiologically indistinguishable from B12 deficiency. [429] [430] [431] [432] [433] Nitrous oxide (N2O) toxicity Analgesic gas commonly abused because of euphoric effects. N2O inactivates vitamin B12 by irreversible oxidation of the cobalt center of methylcobalamine, thereby inhibiting the methionine synthesis pathway. In healthy subjects, this does not cause clinical manifestations. In subclinically B12-deficient individuals, N2O exhausts residual stocks of vitamin B12, leading to neurologic manifestations. [434] [435] [436] Neurolathyrism and neurocassivism Neurolathyrism is caused by consumption of grass pea. Neurocassavism (konzo) is caused by bitter cassava root consumption. Both are found in malnourished populations, and are characterized by subacute paraparesis with prominent UMN features.

May be ependymomas, astrocytomas, or hemangioblastomas. Typically cause an insidious, progressive myelopathy. Hemorrhage or infarction of the tumor may result in an acute presentation and radiologic appearance mimicking TM. 5 Primary CNS lymphoma May give rise to a clinical and radiologic picture mimicking TM compounded by its corticosteroidresponsiveness. Congenital or acquired immunodeficiency is the only established risk factor. More common in middle-aged and older men. Insidious onset of myelopathy with back pain and constitutional symptoms. Serum lactate dehydrogenase may be elevated. CSF: lymphocytic pleocytosis, markedly elevated protein, and hypoglycorrachia. OCBs and IgG index are absent. Cytologic analysis may demonstrate malignant cells (large-volume CSF examination can increase the diagnostic yield). MRI: T2-hyperintensity, gadolinium enhancement, cord swelling, conus medullaris involvement, and concomittant brain lesions. [438] [439] [440] Intravascular lymphoma Predominantly affects vessels in the skin and neurologic system. May mimic TM and even LETM. CSF: lymphocytic pleocytosis and increased protein, but no malignant cells. MRI: affects the conus medullaris (unlike TM). [441] [442] [443] [444] [445] [446] Radiation myelitis Early radiation myelopathy: begins 10-16 weeks after starting radiotherapy with predominantly sensory phenomena (including Lhermitte) and typically resolves spontaneously. Delayed radiation myelopathy: begins months or years following radiation exposure and manifests as a subacute or insidious myelopathy. Concurrent use of chemotherapeutic agents may cause widespread white matter necrosis owing to synergistic toxicity. Preexisting myelopathy from any cause may be risk factors for radiation myelitis. MRI: cord swelling on T1-weighted images, intramedullary T2-hyperintensity, ring-like gadolinium enhancement. [447] [448] [449] [450] Abbreviations: CNS, central nervous system; CSF, cerebrospinal fluid; Ig, immunoglobulin; LETM, longitudinally extensive transverse myelitis; MRI, magnetic resonance imaging; OCB, oligoclonal bands; TM, transverse myelitis; UMN, upper motor neuron.

fondaparinux can be used to prevent venous thromboembolism. 278 Respiratory therapy may prevent atelectasis. In severely weak patients, pressure sores are a serious complication. Addressing risk factors (eg, malnutrition, impaired circulation), conscientious use of pressure-reducing measures (eg, frequent and regular turning, pressure-distributing positioning aids, sheepskins), and early mobilization are critical. 279

Decreased mobility is a factor associated with diminished quality of life (QOL) following spinal cord injury (SC)I. 280 Improving mobility in an energy-efficient manner may thus improve health-related QOL following TM and should be a priority of rehabilitation. 281 Bipedal locomotion is a complex phenomenon that requires intricate interactions between central pattern generators and peripheral reflexes that involve multiple neural networks, including the visual, vestibular, proprioceptive, and corticospinal systems. 282 Walking parameters can be affected by age, weight, spasticity, lower limb strength, balance, pain, duration of rehabilitation, cord lesion level, and the presence of other comorbidities. Functional walking has several requisites, including safety (which dictates the need for walking aids), speed, comfort, and distance. 283 Velocity is one of the most important parameters in determining functional ambulation, particularly community ambulation 283 ; SCI patients have tremendous difficulty achieving the speed needed to cross an intersection safely. 284 Following nontraumatic SCI, although inpatient rehabilitation may improve walking abilities, gait speed often remains impaired and insufficient to safely negotiate community environments. 285 Table 11 describes concepts and strategies in managing mobility following TM.

The benefits of physical exercise extend beyond improvements in strength and functional capacity; mood, fatigue, balance, and QOL can also improve. 286 Exercise also carries anti-inflammatory benefits. 287 Spasticity Spasticity is the velocity-dependent increase in muscle tone owing to disruption of the descending corticospinal, vestibulospinal, and reticulospinal pathways. It often affects the patient by causing muscle stiffness, spasms, pain, and clonus. Paroxysmal tonic spasms are sudden, episodic, brief, painful, stereotypic, dystonic contractions that may occur following TM. 3, 288 Spasticity may result in pain, interrupted sleep, and impaired ambulation. 288 Although some degree of spasticity may protect against osteoporosis, 289 and is needed for weight bearing to allow ambulation, excessive spasticity can disrupt activities of daily living (eg, transferring, hygiene, sexual activity). Successful treatment of spasticity can be attained with an integrated multidisciplinary approach. Table 12 summarizes management options for spasticity.

Movement disorders that may be complicate TM include propriospinal myoclonus (PSM), periodic limb movement disorder (PLMS) and restless leg syndrome (RLS). PSM is an unusual movement disorder, sometimes seen after spinal cord lesions, characterized by myoclonic jerks arising in muscles corresponding to a myelomere (myoclonic generator) and spreading rostrally and caudally to the other myotomes. 290 Drug therapy of PSM is disappointing but there are reports of treatment with benzodiazepines, zonisamide, and valproate.

PLMS and RLS have been reported as a consequence of spinal cord pathologies, including TM, and may be related to the emergence of spasticity. 291 These disorders may impair sleep quality and, as such, should be treated. Serum ferritin levels should be ascertained, as iron-deficiency anemia is a common and treatable cause of RLS. 291 Caffeine, alcohol, nicotine, and medications that may aggravate RLS should be avoided. The first-line choice for pharmacologic therapy is a dopaminergic agonist (eg, ropinorole, pramipexole). Other options include levodopa, opiates, gabapentin, lamotrigine, or clonazepam. 292 

Bladder dysfunction remains one of the most common and disabling consequences of TM 293 ; UTI is the most common medical complication in myelopathic patients. 294 Table 11 Management options for addressing long term mobility issues following transverse myelitis Therapy/Device/ Concept Description References

Focuses on compensatory strategies for nonremediable neurologic deficits. Focuses on strengthening muscles above the level of the lesion, and unaffected muscles below the level of the lesion.

Interventions that provide activation of the neuromuscular system below the level of lesion with the goal of retraining the nervous system to recover a specific motor task. 451 Ankle-foot orthoses (AFOs)

AFOs can support the weakened musculature around the ankle. AFOs address excess plantar flexion during initial contact, stabilize the ankle for effective push-off during late stance, and prevent toe-drag during swing. 452 Functional electrical stimulator devices

Can reduce toe drag, circumduction, pelvic obliquity, and genu recurvatum, improving energy efficiency and facilitating safety and walking duration. Long-term use results in stable improvements of walking performance that persist even when the device is turned off. Adherent use of a dorsiflexion assist device may enhance the fidelity of activation of motor cortical regions and the descending corticospinal connections that control the swing phase of ambulation. 286, 453, 454 Robot-assisted gait training Different systems are commercially available, including the "Lokomat," the "LokoHelp," and the "Gait trainer." 455 Neuromuscular electrical stimulation (NMES)

Helpful in improving interlimb coordination during locomotion 456 Dalframpridine Dalframpridine is the extended-release, oral form of 4-aminopyridine approved by the Food and Drug Administration that has been shown to improve the walking ability in patients with multiple sclerosis by improving conduction along demyelinated axons. 457 

Despite complete motor recovery following TM, bladder dysfunction often persists. 295 In general, 3 forms of bladder dysfunction may be present: detrusor overactivity (failure to store), detrusor-sphincter dyssynergia (DSD), and detrusor hypocontractility (failure to empty). In acute TM, urinary retention from a hypocontractile "shocked" bladder (detrusor areflexia or hyporeflexia) often necessitates placement of a urinary catheter. 293, 295 Similar to how UMN signs appear following spinal shock, detrusor hyperreflexia typically develops, characterized by frequency, urgency, urge incontinence, and the sensation of bladder spasms 295, 296 ; in fact, the resolution of spinal shock and subsequent emergence of UMN signs may parallel similar changes in the bladder. 293 Some patients experience DSD, where insufficient external urinary sphincter relaxation during detrusor contraction results in urinary retention, increasing the risk for vesicoureteral reflux, infection, and nephrolithiasis. 296 Patients with DSD can also report urgency, frequency, incontinence, urinary hesitancy, and a sensation of incomplete bladder emptying after voiding. 297 More infrequently, a hypotonic, overly compliant bladder (failure to empty) may present with frequency, overflow incontinence, and signs of incomplete emptying. 297, 298 Urinary symptoms are unreliable in differentiating poor bladder compliance from urinary retention. 3 Although ultrasonographic assessment of postvoid residual urine volume is useful, urodynamic studies (and hence, urologic consultation) and renal ultrasound are often required to properly characterize the nature of bladder dysfunction, plan management, and identify those at risk for future complications. 295, 298 Table 13 summarizes the various problems of bladder dysfunction and management options.

TM may result in gastrointestinal dysfunction following perturbation of the autonomic pathways of the spinal cord. In the setting of spinal shock, there is an increased risk for gastroduodenal ulceration and hemorrhage, paralytic ileus, acute gastric dilatation, and atypical presentations of acute abdominal pathology. 299 Table 12 Management options for spasticity in patients with transverse myelitis

Nonpharmacologic measures Physical therapy, stretching exercises, orthotics, and aquatic therapy Useful for mild cases.

Baclofen Tizanadine Dantrolene (must monitor liver function tests) Anticonvulsants Benzodiazepines Anticonvulsants and benzodiazepines are useful for paroxysmal tonic spasms. Sedation may limit the use of the above-mentioned drugs.

Particularly useful for nonambulatory patients with severe adductor spasms that complicate adequate perineal hygiene.

Intrathecal baclofen (ITB) May be used when oral medications cause too much sedation. Patients must be carefully evaluated before ITB use because of serious risks associated with baclofen withdrawal.

Gastroparesis (presenting with nausea, vomiting, pain, bloating, and/or early satiety) increases the risk of reflux and aspiration of gastric contents. It has been reported following cervical cord, thoracic cord, and cervico-medullary junction lesions. [300] [301] [302] [303] Avoid alcoholic and caffeinated beverages after 5 PM, to limit fluid intake in the evening, to avoid any fluids 2 h before bedtime and to void before going to bed.

Data from Refs. 3, 297, 298, [458] [459] [460] [461] [462] [463] [464] [465] Transverse Myelitis

Gastroparesis may occur in the acute and chronic phases of TM. Table 14 summarizes the management of gastroparesis.

Bowel dysfunction is a source of considerable psychosocial disability, limiting the ability to work and affecting patients' QOL. 304 It may manifest as either constipation or fecal incontinence. The exact pathophysiology of bowel dysfunction in TM is unclear, but may because of disruption of the extrinsic neurologic control of gut and sphincter function, pelvic floor musculature, autonomic dysfunction, and/or impaired anorectal sensation. 304 Psychiatric disorders and medications also contribute to bowel dysfunction. For example, although opioid narcotics and anticholinergic drugs cause constipation, baclofen can theoretically alter the response to rectal distension and the threshold of conscious rectal sensation and cause fecal incontinence. 304 Management strategies for neurogenic bowel dysfunction are summarized in Table 14 .Transanal irrigation (TAI) can be carried out using either a rectal balloon catheter or a cone-shaped colostomy tip. In a retrospective study of 348 patients (either constipation or fecal incontinence) during a 10-year period, TAI showed benefit in treating neurogenic bowel dysfunction. 305

Hemorrhoids (and hemorrhage) are more frequent in patients with bowel dysfunction and is likely a consequence of straining and the use of suppositories and enemas. 299 Gallbladder disease is also more prevalent following SCI. 299 Superior mesenteric artery syndrome (where the third part of the duodenum is intermittently compressed by the vessel) causes vomiting when supine. Rapid weight loss, prolonged supine positioning, and the use of spinal orthosis are predisposing factors. 299 

Sexuality is a fundamental aspect of health at the core of individual identity and influences a person's well-being. 306 Sexual dysfunction is a frequent complication of spinal cord lesions and has been shown to increase the risk of suicide. 307 As the incidence of TM is higher in the second and fourth decades of life, it affects adolescents or young adults who are sexually active.

Sexual dysfunction may be a direct consequence of damage to the autonomic and sensory pathways in the spinal cord following TM. Indirectly, complications of TM, including the psychological response to disability, spasticity, immobility, pressure ulcers, pain, and sphincter dysfunction, affect sexual function. Psychological dysfunction contributes more to sexual dysfunction than the actual physical disabilities. 308 Comorbidities (eg, mood disorders, diabetes) and medications are other important contributors to sexual dysfunction.

An open, frank, and nonjudgmental discussion about sexual function, expectations, beliefs, preferences, and the potential complications from TM should be undertaken with the patient. Including the patient's partner in such discussions is often helpful. A medical assessment of the reproductive system should be conducted as part of the multidisciplinary approach to TM. 306 Skin, bladder, and bowel care before sexual activity is important. 306 Autonomic dysreflexia (see later in this article) is a potentially dangerous consequence of sexual activity. Because of diminished or absent sensation, skin breakdown may occur from excessive friction, and in men, there is an increased risk of penile trauma.

Following spinal cord damage, most men can have some form of erection (psychogenic or reflexogenic) but these are often insufficiently predictable, rigid, or long lasting to allow sexual intercourse. [309] [310] [311] Only 25% of men with SCI have erections adequate for sexual intercourse 312 ; erectile dysfunction is a great source of distress in men with SCI, even more so than the loss of functional independence or sphincter dysfunction. 313 A precise coordination of sympathetic, parasympathetic, and somatic 

Stop drugs that inhibit gastrointestinal motility (eg, narcotics, calcium channel blockers, anticholinergics). Consultation with a gastroenterologist for endoscopy, gastric emptying studies, and investigations to characterize the nature of dysmotility. Gastric decompression with a nasogastric tube, bowel rest, intravenous fluids, and proton-pump inhibitors or gastric H2-receptor blockers should be considered. Prokinetic agents (eg, metoclopramide, macrolide antibiotics, bethanecol or pyridostigmine) may be used. Tardive dyskinesia is a risk of metoclopramide use. Gastric electrical stimulation (Enterra therapy) and endoscopic injection of botulinum neurotoxin may be of potential benefit. In refractory cases, surgical interventions like pyloroplasty may be needed.

General measures: high-fiber diet, bulking agents, increased fluid intake (at least 2 L daily), physical exercise, and establishing a regular toileting routine (best accomplished after breakfast to take advantage of the gastrocolic response, which peaks about 30 minutes after eating). Stimulant or osmotic laxatives (senna and bisacodyl) can be titrated to produce a satisfactory response (without producing liquid stool). Osmotic laxatives, although effective, can produce liquid stool with subsequent incontinence. Rectal stimulants have a predictable time of response. Begin with a glycerine suppository, progressing to bisacodyl, sodium citrate microenema, and ultimately a phosphate enema. Biofeedback may help, particularly in pelvic floor incoordination. Neostigmine in combination with glycopyrrolate has been shown to be effective. 4-aminopyridine may improve constipation. Digital stimulation of the anal canal serves to manually disimpact the rectum. Abdominal massage may be helpful. For refractory cases: colostomy, neuromodulation, Malone Antegrade Continence Enema. Transanal irrigation (TAI).

Fecal incontinence Mild and infrequent: loperamide, codeine phosphate.

Antidiarrheal drugs should be used with caution if incontinence and constipation coexist, and periodic checks for impaction may be required. Fecal impaction is a common complication and patients experience anorexia, nausea, and spurious diarrhea (liquid stool passing around the blockage). Biofeedback is another useful tool. Anal plugs or pads may be needed. Severe cases: surgical intervention (eg, dynamic graciloplasty, artificial bowel sphincter, and sacral nerve stimulation). TAI Data from Refs. 299, 304, 305, 466, 467 Transverse Myelitis divisions of the nervous system is essential for normal antegrade ejaculation. This intricate neural network is easily disrupted following spinal cord damage, leading to ejaculatory dysfunction and, hence, infertility. Intact genital sensation is the most important positive predictive factor of male sexual function, whereas an important negative predictor of sexuality is the presence of spasticity. 314 The effects of spinal cord lesions on female sexuality is much less studied than in males, mainly because of the preponderance of male patients with traumatic SCI and partly because female fertility is not affected. 308, 315 Manifestations include decreased libido, lack of arousal, vaginal dryness, dyspareunia, and decreased genital sensation. 316 An important point to emphasize to all patients is that although genital sensation is diminished, individuals are more likely to develop new erotogenous areas above the level of the lesion, or with time, learn to interpret altered autonomic input from genitoperineal stimulation 317, 318 ; it is, therefore, important to explore new methods of sexual expression. Also, access to programs for sexual rehabilitation that include a multidisciplinary spinal cord team, as well as support groups, may be a pivotal part of treatment. Table 15 summarizes some management strategies for sexual dysfunction.

Autonomic dysfunction may occur in the acute or chronic phases of TM and appears to be present in lesions above the upper thoracic segments.

Acute spinal cord lesions may cause neurogenic shock. In addition, cardiac dysrhythmias (eg, bradycardia and arrest) may occur. 319 Initial management may require hemodynamic monitoring and management in an intensive care setting.

Orthostatic hypotension (OH) may occur in both the acute and chronic phases of TM. OH is defined as a decrease in systolic blood pressure of 20 mm Hg or more or a decrease in diastolic blood pressure of 10 mm Hg or more when the subject moves from an upright to supine posture, regardless of whether symptoms occur. 320 Clinical manifestations include pallor, diaphoresis, light-headed dizziness, syncope, anxiety, and nausea.

It is more common with lesions above the upper thoracic spinal segments. 321 Loss of sympathetic nervous activity and reflex vasoconstriction lead to pooling of venous blood in the abdominal organs and lower limbs; ultimately, cardiac output (and arterial pressure) drops. The reflex tachycardia that occurs often cannot adequately compensate for this. Cerebral hypoperfusion from reduced cardiac output is responsible for its manifestations.

Although classically reported following traumatic SCI, thermodysregulation is another potential complication of TM with lesions at T6 and above; it can be classified as poikilothermia, "quad fever," and exercise-induced hyperthermia. 319 Disruption of the interomediolateral columns of the spinal cord and hypothalamic lesions likely contribute to thermodysregulation following TM. 322 Perturbed heat dissipation mechanisms, in particular defective sweating (possibly owing to disruption of the descending sudomotor pathways), is believed to be a major contributor to thermodysregulation. Urinary dysfunction following TM often leads to voluntary restriction of fluid intake; further exacerbating thermodysregulation. 323 "Quad fever" can occur in the acute phase and patients often present with fever. 319 Needless to say, a thorough workup should be undertaken to rule out infection, thromboembolism, inflammation, and atelectasis before attributing pyrexia to "quad fever." Exercise-induced hyperthermia as a result of Uhthoff phenomenon and heatinduced fatigue is important to recognize. 323 Approximately 60% to 80% of patients with MS experience transient worsening of neurologic symptoms as a result of elevated body temperature (ie, Uhthoff phenomenon). 323 In addition to defective sweating (hypohidrosis), profuse sweating (hyperhidrosis) can occur above the level of the lesion with little or no sweating below it. Episodic hyperhidrosis may be associated with episodes of autonomic dysreflexia. 319 

Autonomic dysreflexia (AD) is a well-recognized chronic complication of SCI and may occur following TM. It usually occurs in subjects with lesions above the outflow to the splanchnic and renal vascular beds (T5-6). AD is characterized by paroxysms of excessive, uninhibited sympathetic output leading to hypertension, bradycardia (although tachycardia may occur), pounding headache, piloerection, nasal congestion, anxiety, nausea, chills and shivering, flushing, and profuse sweating above the level of the lesion 319, [324] [325] [326] ; severe cases may result in myocardial ischemia, seizures, retinal detachment, intracranial hemorrhage, hypertensive emergency, reversible posterior leukoencephalopathy, and even death. 325, [327] [328] [329] The higher the level of the lesion, the more severe the cardiovascular dysfunction; complete SCI is associated with a higher incidence of AD compared with incomplete lesions. 325 Any stimuli below the affected spinal level may precipitate AD, including bladder catheterization, manipulation of an indwelling catheter, DSD, UTI, bladder percussion, sexual activity, fecal impaction, pressure sores, ingrown toenails, sacral stress fracture, and use of devices for ejaculation. 319, 325, [330] [331] [332] In most cases, AD is related to bladder distention or bowel impaction. 325, 333 Table 16 summarizes the management strategies for AD.

Sensory phenomena are a common complication of TM. Early recognition and intervention may prevent chronic pain syndromes. 261 TM-related pain may be classified as nociceptive or neuropathic. Nociceptive pain is related to musculoskeletal and visceral (eg, biliary colic) sources. Neuropathic pain may be related to complex regional pain syndromes, segmental deafferentation, radiculopathy, or cord damage. Two unique types of neuropathic pain are recognized: (1) a segementally distributed radicular pain at the level of the lesion; and (2) a late-onset central dysesthesia syndrome below the level of the lesion, characterized by a stimulus-independent, continuous pain. 334 Treatments include oral tricyclic antidepressants, anticonvulsants, serotoninnorepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, or narcotics. Lidocaine patches, topical capsaicin, and botulinum neurotoxin are other options. 3, 297 Anticonvulsants may be useful for Lhermitte phenomenon. 335 Biofeedback, physical therapy, acupuncture, and transcutaneous electrical nerve stimulation are nonpharmacologic measures that can be considered. Dorsal root entry zone ablation is useful for radicular pain at the level of the lesion. Consultation with a pain management team may be needed.

A rare complication of TM is neurogenic pruritus, characterized by a dermatomal distribution of pruritus that is often associated with hypoesthesia or hyperesthesia; it responds poorly to medical therapy. 336 

Osteoporosis is a known complication of SCI 337,338 and may be a consequence of both the cord lesion, subsequent immobilization, and neuroendocrinological dysfunction. 339, 340 The duration of paralysis correlates with the degree of bone loss. 340 The pathobiological underpinnings of bone demineralization are unclear and, interestingly, its pattern differs from that seen in endocrine-related osteoporosis. 339 Bone loss begins immediately after SCI and is greater below the level of the lesion. In the first months, demineralization occurs exclusively in the sublesional areas and predominantly in weight-bearing skeletal sites. 339, 340 The largest decrease in bone mass occurs during the first 6 months after injury and stabilizes after 12 to 16 months, at which point approximately two-thirds of the original bone mass is close to the threshold for pathologic fractures. 341 Hypercalcemia and hypercalciuria resulting from increased bony resorption may increase the risk of nephrolithiasis. 339, 340 Women are at greater risk of osteoporosis following SCI. 340 Supplementation with calcium and vitamin D is a cost-effective and easily implemented method of addressing bone loss. Physical exercise (weight-bearing activities, verticalization, and aided-walking systems) has been shown to have an osteogenic influence in healthy subjects and in those with SCI. Functional electrical stimulatorinduced mechanical loading has also been shown to conserve bone density, but this benefit is seen only if it is started as early as possible following spinal cord damage (less than 6 months postinjury). Bisphosphonates and salmon calcitonin are potentially beneficial therapies. 339 

Vitamin D deficiency is commonly found in patients with both acute and chronic SCI. 342 It may lead to elevated parathyroid hormone levels that subsequently increase Table 16 Management strategies for autonomic dysregulation following transverse myelitis

Orthostatic hypotension Nonpharmacologic: increasing fluid intake; a high salt diet (>8 g/d); avoiding a hot environment; avoiding large carbohydrate-rich meals; avoiding prolonged recumbency; application of external counterpressure (eg, abdominal binding, compression stockings); functional electrical stimulator devices (induces intermittent muscle contractions and therefore increasing venous return); exercise training may also induce positive changes in autonomic cardiovascular regulation. Pharmacologic: midodrine; L-threo-3,4-dihydroxyphenylserine (L-DOPS); fludrocortisone.

Thermodysregulation Adequate hydration. Exercising or working during cooler hours of the day. Cold showers. Regional cooling devices. Precooling by immersing the lower extremities in cold water before thermal stress, allows the lower limbs to serve as "heat sinks." Dalframpridine.

Acute Management Identify the possible trigger and decrease afferent stimulation. Sit the patient up to cause an orthostatic decrease in the blood pressure. Loosen the clothing and other constrictive devices. Check the blood pressure every 2-5 minutes until the patient is stable. The best antihypertensive medications have a rapid onset and short duration of action (eg, nitrates, hydralazine and immediate-release nifedipine); 10 mg nifedipine may be given using the "bite and swallow" method. Alternatively, 1 inch of 2% nitropaste can be applied above the level of the lesion and wiped off when the hypertensive episode subsides.

Preventative measures are the most effective approach.

Prevention of pressure sores and addressing urinary and bowel dysfunction are imperative. Individuals should carry a medical emergency card for AD. Pharmacologic prevention: Alpha-1 antagonists (terazosin and prazosin); gabapentin; prostaglandin E2; phenozybenzamine.

Data from Refs. 323, 325, [473] [474] [475] [476] [477] [478] [479] [480] Transverse Myelitis bone loss. 343 Aside from its role in osteoporosis, Vitamin D is important in the immunopathogenesis of TM. Low vitamin D levels have been linked to TM 344 as well as various autoimmune disorders, including MS, 345,346 SLE, 347 and AS. 348 In MS, suboptimal vitamin D levels increase the relapse rate as well as the risk of developing the disease. Interestingly, low vitamin D levels have been shown to correlate with an increased risk for recurrent TM. 349, 350 The immunologic role of vitamin D is fascinating but remains unclear. Reductions in proinflammatory agents, such as interleukin (IL)-6, IL-1-beta, gammainterferon, and IL-17 have been observed with vitamin D supplementation. 351, 352 Optimal vitamin D levels have been shown to suppress Th17-mediated autoimmunity 353 and augment T-cell regulatory cell populations, providing a putative mechanism for preventing autoimmunity. 354 Factors contributing to vitamin D deficiency include inadequate dietary intake and sun exposure. The primary source of vitamin D in humans is sunlight. 355 TM-related complications, including immobility and thermodysregulation, as well as photosensitivity in some autoimmune disorders, limit sunlight exposure. Many patients also harbor the misconception that consuming foods with calcium and vitamin D causes nephrolithiasis. 342 The use of hepatically metabolized anticonvulsants to treat various complications of TM further exacerbates vitamin D deficiency. 356 The "normal" value of 25-hydroxyvitamin D levels remains 10 to 20 ng/mL in many institutions and commercial laboratories. 342 Unfortunately, recommendations about vitamin D intake from health agencies lags behind developments in the field. 357 An amount of 5000 IU per day has been shown to reduce the number of MS relapses 358 and intakes up to 10,000 IU per day appear safe. 359 Vitamin D3 appears superior to vitamin D2 360 and is available at all retail pharmacies in the United States for a low price. Patients seen at the neuroimmunologic disease clinic at our institution are encouraged to take between 5000 and 10,000 IU of vitamin D3 daily to achieve serum levels of between 60 and 80 ng/mL.

Adequate vitamin D levels have several other notable benefits, including a decreased risk of breast and colon cancer, 361, 362 improved muscle strength, 363 decreased frequency of falls, 364 and diminished musculoskeletal pain. 365 

In patients presenting for the first time with TM, consultation with a clinical psychologist or psychiatrist is valuable in addressing its understandably devastating impact on the patient's QOL. Indeed, a recent study found that almost 90% of parents of children with TM perceive a need for psychiatric care but only a quarter receive it. 277 The loss of functional independence, along with sphincter and sexual dysfunction, would be expected to negatively affect the patient's psychological constitution and adversely affect future expectations. Mood disorders and emotional changes following TM may also be a consequence of the pathobiological changes engendered by the underlying disease process. Mood disorders, fatigue, and cognitive impairment are well-recognized sequelae of MS and autoimmune disorders like BD, SS, and SLE. 56, 102, 103, 105, 366 Additionally, certain immunomodulatory drugs (eg, interferonbeta) may cause depression. 367 Recognition of the neuropsychiatric symptoms associated with TM is important because it affects the patient's QOL. Formal neuropsychological testing may help identify the mood disorder or cognitive domain(s) affected. Consultation with a clinical psychologist and/or psychiatrist is useful is deciding if the patient can be managed with counseling, psychotherapy, group therapy, and/or pharmacotherapy. Cognitive dysfunction may be treated with memantine or anticholinesterase inhibitors like donepezil. 297 SUMMARY TM constitutes a pathobiologically heterogeneous syndrome, with immune-mediated, inflammatory damage of the spinal cord at its core. A detailed history and thorough physical examination are indispensible. The most important investigation to undertake is an MRI of the entire spinal axis and the brain. The location and length of the lesion are important discriminators with etiologic and prognostic significance.

APTM is commonly attributable to MS. Although LETM is characteristic of NMO, longitudinally extensive lesions may occur in other diseases as well. The brain MRI and CSF OCBs are powerful predictors of conversion to MS. NMO-IgG seropositivity has a high specificity for NMO.

The epidemiologic, clinical, radiologic, and longitudinal data seen in pediatric TM suggests that the pathobiological underpinnings are distinct from TM in the adult population. As such, caution should be exercised when applying findings from studies in the adult population to children and vice versa.

Although the application of set criteria for diagnosing ITM has resulted in a fairly homogeneous group of patients (clinically and radiologically), it remains possible that recurrent ITM represents a unique disease entity. More longitudinal studies are needed to elucidate the nature of recurrent ITM.

Zum Capitel der Myelitis

Acute transverse myelitis: is the "idiopathic" form vanishing?

Clinical practice. Transverse myelitis

Acute myelopathies: clinical, laboratory, and outcome profiles in 79 cases

An approach to the diagnosis of acute transverse myelitis

Postinfectious encephalomyelitis

Transverse Myelitis Consortium Group. Proposed diagnostic criteria and nosology of acute transverse myelitis

Acute transverse myelitis: incidence and etiologic considerations

Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events

The epidemiology of transverse myelitis

Long-term outcome of acute and subacute myelopathies

Clinical course and long-term prognosis of acute transverse myelopathy

Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Transverse Myelitis 115

Spinal shock revisited: a four-phase model

Compressive and traumatic myelopathies

Phantom limb sensations after complete thoracic transverse myelitis

The Lhermitte phenomenon: variant forms and their significance

Myeloneuropathy after prolonged exposure to nitrous oxide

Priapism in acute spinal cord injury

Priapism in infantile transverse myelitis

Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility and clinical characteristics

Localization in clinical neurology

The neurologic exam as a lesson in neuroanatomy

The clinical course of neuromyelitis optica (Devic's syndrome)

Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers

Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis

Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord

Nosology of idiopathic transverse myelitis syndromes

Acute partial transverse myelitis with normal cerebral magnetic resonance imaging: transition rate to clinically definite multiple sclerosis

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis

A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index. A comparison and diagnostic applications

Referral patterns of uveitis in a tertiary eye care center

The neuro-ophthalmology of multiple sclerosis

Absent F-waves early in a case of transverse myelitis

Can electromyography predict the prognosis of transverse myelitis?

Multiple sclerosis-the plaque and its pathogenesis

Prospective study of patients presenting with acute partial transverse myelopathy

Discriminatory features of acute transverse myelitis: a retrospective analysis of 45 patients

Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases

Acute partial transverse myelitis: risk factors for conversion to multiple sclerosis

Long-term follow-up of acute partial transverse myelitis

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

Importance of paraclinical and CSF studies in the diagnosis of MS in patients presenting with partial cervical transverse myelopathy and negative cranial MRI

The prognostic value of brain MRI in clinically isolated syndromes of the CNSA 10-year follow up

Acute myelopathy of unknown etiology: a clinical, neurophysiological and MRI study of short and long-term prognostic factors

Acute transverse myelitis with normal brain MRI: long-term risk of MS

Longitudinally extensive myelopathy in Caucasians: a West Australian study of 26 cases from the Perth Demyelinating Diseases Database

Revised diagnostic criteria for neuromyelitis optica

Neuromyelitis optica and non organspecific autoimmunity

The spectrum of neuromyelitis optica

Frequency and specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders

Classification criteria for Sjö gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

CNS involvement in primary Sjogren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach

Neurologic manifestations in primary Sjö gren syndrome: a study of 82 patients

Neurologic complications of primary Sjö gren's syndrome

Central nervous system disease in Sjö gren's syndrome

Sjö gren's syndrome myelopathy: spinal cord involvement in Sjogren's syndrome might be a manifestation of NMO

Acute transverse myelopathy successfully treated with plasmapheresis and prednisone in a patient with primary Sjogren's syndrome

Intravenous gammaglobulin in the treatment of central nervous system vasculitis associated with Sjö gren's syndrome

Rituximab therapy in primary Sjö gren's syndrome

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

Neuropsychiatric lupus

A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis

Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature

Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases

Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients

Distinct subtypes of myelitis in systemic lupus erythematosus

Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies

Longitudinal myelitis associated with systemic lupus erythematosus: clinical features and magnetic resonance imaging of six cases

Lupus-related myelitis: serial MR findings

Spinal cord involvement and systemic lupus erythematosus: clinical and magnetic resonance findings in 5 patients

Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome

Longitudinal involvement of the spinal cord in a patient with lupus related transverse myelitis

Involvement of the entire spinal cord and medulla oblongata in acute catastrophic-onset transverse myelitis in SLE

Longitudinal myelitis, aseptic meningitis, and conus medullaris infarction as presenting manifestations of pediatric systemic lupus erythematosus

Demyelination in rheumatic diseases

Controlled clinical trial of IV cyclophosphamide versus IV methylprenisolone in severe neurological manifestations in systemic lupus erythematous

Transverse myelitis in patients with antiphospholipid antibodies-the importance of early diagnosis and treatment

Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment

The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus

Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients

SLE-associated transverse myelitis successfully treated with rituximab (anti-CD20 monoclonal antibody)

Rituximab in the treatment of severe lupus myelopathy

Prognostic factors of lupus myelopathy

International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients

Recurrent transverse myelitis in primary antiphospholipid syndrome: case report and literature review

Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature

Acute transverse myelitis as part of the catastrophic antiphospholipid syndrome in a systemic lupus erythematosus patient

Neurological manifestations of antiphospholipid syndrome

Systemic autoimmune features and multiple sclerosis. A 5-year follow up

Prevalence and clinical significance of antiphospholipid antibodies in multiple sclerosis: a study of 89 patients

Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients

MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis

Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis

The International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease

Neuro-Behcet's disease: epidemiology, clinical characteristics, and management

Clinical characteristics and course of spinal cord involvement in Behcet's disease

Neurological manifestations of Behcet's disease in Japan: a study of 54 patients

Clinical patterns of neurological involvement in Behç et's disease: evaluation of 200 patients

Multifocal myelitis in Behcet's disease

CNS involvement in neuro-Behcet syndrome: an MR study

Neurological involvement in North Italian patients with Behcet's disease

MRI findings in neuro-Behcet's disease

Subacute longitudinal myelitis associated with Behcet's disease

Magnetic resonance imaging of the central nervous system in Behcet's disease

Spinal cord MRI in neuro-Behcet's disease

MRI of spinal cord involvement in Behcet's disease: case report

Spinal cord neuro-Behcet's disease detected on magnetic resonance imaging

Transverse myelitis after lumbar steroid injection in a patient with Behcet's disease

Reversibility of brain lesions in a case of neuro-Behcet's disease studied by MR diffusion

Neurological complications in Behç et's syndrome

Masked assessment of MRI findings: is it possible to differentiate neuro-Behcet's disease from other central nervous system

A case of neuro-Behcet's disease presenting with lumbar spinal cord involvement

Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature

Biochemical mechanisms of cyclosporine neurotoxicity

Central nervous system symptoms in patients with Behç et disease receiving cyclosporine therapy

Central nervous system symptoms in a population of Behç et's disease patients with refractory uveitis treated with cyclosporine A

CNS involvement occurs more frequently in patients with Behç et's disease under cyclosporin A (CSA) than under other medications: results of a retrospective analysis of 117 cases

Diagnosis and management of neurological sarcoidosis

Neurosarcoidosis: signs, course and treatment in 35 confirmed cases

Sarcoidosis and its neurological manifestations

Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases

Sarcoidosis of the spinal cord: literature review and report of eight cases

Neurosarcoidosis: a study of 30 new cases

Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study

MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment

Intramedullary cervical spinal cord sarcoidosis

Isolated spinal neurosarcoidosis: an autopsy case

Sarcoidosis presenting as "corset-like" myelopathy: a description of six cases and literature review

Clinical description of 7 cases with a proposal for a new diagnostic strategy

Clinical and magnetic resonance imaging manifestations of neurosarcoidosis

Spinal neurosarcoidosis mimicking an idiopathic inflammatory demyelinating syndrome

Clinical features of spinal cord sarcoidosis: analysis of 17 neurosarcoidosis patients

Central nervous system sarcoidosisdiagnosis and management

Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis

Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis

Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis

Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of the international committee on nomenclature

VKH syndrome with focal neurological signs

MRI documented acute myelitis in a patient with Vogt-Koyanagi-Harada syndrome: first report

Vogt-Koyanagi-Harada disease presenting as optic neuritis

Neurotological evaluation of Harada's disease

Influence of early cerebrospinal fluid-guided diagnosis and early high-dose corticosteroid therapy on ocular outcomes of Vogt-Koyanagi-Harada disease

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Acute disseminated encephalomyelitis

Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins

A case of acute disseminated encephalomyelitis (ADEM) associated with demyelinating peripheral neuropathy

Clinical study of childhood acute disseminated encephalomyelitis, multiple sclerosis, and acute transverse myelitis in Fukuoka Prefecture

Post-vaccination encephalomyelitis: literature review and illustrative case

Role of MRI in the differentiation of ADEM from MS in children

Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis

Serial magnetic resonance imaging in children with postinfectious encephalitis

Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases

Acute disseminated encephalomyelitis: pathogenesis, diagnosis, treatment, and prognosis

Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: a successful recovery

Role of plasmapheresis in acute disseminated (post-infectious) encephalomyelitis

A randomized trial of plasma exchange in acute CNS inflammatory demyelinating disease

Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months

Plasma exchange for severe attacks of CNS demyelination: predictors of response

Immune-mediated myelitis associated with hepatitis virus infections

Spinal cord biopsy findings of anti-aquaporin-4 antibody-negative recurrent longitudinal myelitis in a patient with sicca symptoms and hepatitis C viral infection

Severe recurrent myelitis in patients with hepatitis C virus infection

Recurrent myelopathy and hepatitis C infection

Recurrent demyelinating myelitis associated with hepatitis C viral infection

Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease

Acute transverse myelitis following hepatitis E virus infection

Acute transverse myelitis following dengue virus infection

Parainfectious encephalomyeloradiculitis associated with herpes simplex virus 1 DNA in cerebrospinal fluid

Longitudinally extensive transverse myelitis associated with dengue fever

Acute transverse myelitis associated with dengue viral infection

Viral myelitis: an update

West Nile encephalitis and myelitis

Japanese encephalitis

MR findings in Murray Valley encephalitis

Severe tick borne encephalitis with simultaneous brain stem, bithalamic, and spinal cord involvement documented by MRI

Parainfectious myelitis associated with parvovirus B19 infection

Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen

Chikungunya and the nervous system: what we do and do not know

Central nervous system complications following Hanta virus cardiopulmonary syndrome

Transverse myelitis due to echovirus type 30

Central nervous system manifestations associated with serologically verified Mycoplasma pneumoniae infection

Mycoplasmas as agents of human disease

CNS manifestations associated with Mycoplasma pneumoniae infections: summary of cases at the University of Helsinki and review

Mycoplasma pneumoniae-associated myelitis: a comprehensive review

MR imaging of acute transverse myelitis (myelopathy)

Extensive myelitis associated with Mycoplasma pneumoniae infection: magnetic resonance imaging and clinical long-term follow-up

Transverse myelitis as a rare, serious complication of Mycoplasma pneumoniae infection

Acute transverse myelitis as a rare manifestation of Campylobacter diarrhoea with concomitant disruption of the blood brain barrier

Campylobacter jejuni-induced acute transverse myelitis

Severe myelitis following infection with Campylobacter enteritis

Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni

Acute disseminated encephalomyelitis temporally associated with Campylobacter gastroenteritis

Acute disseminated encephalomyelitis associated with Campylobacter jejuni infection and antiganglioside GM1 IgG antibodies

Postinfectious encephalopathy in a child following Campylobacter jejuni enteritis

Acute transverse myelitis in Lyme neuroborreliosis

Acute transverse myelitis secondary to Salmonella paratyphi B infection

Transverse myelitis associated with Acinetobacter baumanii intrathecal pump catheter-related infection

Acute transverse myelitis associated with Coxiella burnetii infection

Transverse myelitis: unusual sequelae of neonatal group B streptococcus disease

Transverse myelitis associated with cat-scratch disease in an adult

Transverse myelitis associated with probable catscratch disease in a previously healthy pediatric patient

As sick as a pigeon

Acute transverse myelitis associated with Chlamydia psittaci infection

Acute disseminating encephalomyelitis following Legionnaires disease

Acute transverse myelitis associated with scrub typhus: case report and a review of literature

Mycobacteria infection in incomplete transverse myelitis is refractory steroids: a pilot study

Recurrent transverse myelitis following neurobrucellosis: immunologic features and beneficial response to immunosuppression

Transverse myelitis in 2 patients with Bartonella henselae infection (cat scratch disease)

Cryptococcus myelitis: atypical presentation of a common infection

Myelitis caused by Cladophialophora bantiana

Toxocara canis myelitis: clinical features, magnetic resonance imaging (MRI) findings, and treatment outcome in 17 patients

Toxocara canis meningomyelitis

Toxocariasis of the CNS simulating acute disseminated encephalomyelitis

Toxocariasis presenting as encephalomyelitis

Spinal gnathostomiasis resembling an intrinsic cord tumor/myelitis in a 4-year-old boy

Transverse myelitis due to trypanosomiasis in a middle aged Tanzanian man

Transverse myelopathy in the antiphospholipid antibody syndrome: pinworm infestation as a trigger?

Acute myelitis in early Borrelia burgdorferi infection

Uncommon manifestations of neuroborreliosis in children

Acute transverse myelitis and Guillain-Barre overlap syndrome with serological evidence for mumps viraemia

Transverse myelitis following mumps in an adulta case report with MRI correlation

Atypical transverse myelitis due to cytomegalovirus in an immunocompetent patient

Acute transverse myelitis caused by Coxsackie virus B4 infection: a case report

Acute transverse myelitis caused by Coxsackie virus B5 infection

Study in the therapy of transverse myelitis occurring during tuberculous meningitis

Neurological manifestations of Enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia

Successful treatment of Epstein-Barr virus-induced transverse myelitis with ganciclovir and cytomegalovirus hyperimmune globulin following unrelated bone marrow transplantation

Case report: transverse myelitis associated with Epstein-Barr virus infection

Severe neurological complications in association with Epstein-Barr virus infection

MRI studies of spinal visceral larva migrans syndrome

MRI findings of spinal visceral larva migrans of Toxocara canis

Spinal schistosomiasis: differential diagnosis for acute paraparesis in a U.S. resident

Optic neuritis after influenza vaccination

Bilateral optic neuropathy associated with influenza vaccination

Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G

Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5 IgG

Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction

Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis

Atopic myelitis: first case report outside Japan?

Atopic myelitis: a clinical, biological, radiological and histopathological diagnosis

Clinical, immunological and MRI features of myelitis with atopic dermatitis (atopic myelitis)

Acute myelitis associated with hyperIgEemia and atopic dermatitis

First diagnostic criteria for atopic myelitis with special reference to discrimination from myelitis-onset multiple sclerosis

Atopic optic neuritis

Idiopathic acute transverse myelitis: application of the recent diagnostic criteria

Transverse myelitis: pathogenesis, diagnosis and treatment

The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro

Idiopathic transverse myelitis: MR characteristics

Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings

Clinically isolated acute transverse myelitis: prognostic features and incidence

Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis

NMO-IgG-negative relapsing myelitis

Idiopathic recurrent transverse myelitis

Acute transverse myelitis in childhood: center-based analysis of 47 cases

The demographic, clinical and magnetic resonance imaging (MRI) features of transverse myelitis in children

MRI findings in acute idiopathic transverse myelopathy in children

Acute transverse myelitis in children: clinical course and prognostic factors

Acute transverse myelitis in childhood: nine cases and review of the literature

Acute transverse myelopathy in childhood

Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: spectrum or separate entities?

Acquired transverse myelopathy in children in the United Kingdom-a 2 year prospective study

Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders

The rescue effect of plasma exchange for neuromyelitis optica

Neurologic indications for therapeutic plasma exchange: an update

Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide

Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy

Preliminary analysis of a trial of pulse cyclophosphamide in IFN-betaresistant active MS

Transverse myelitis

Neurorehabilitation in multiple sclerosis: foundations, facts and fiction

Quality care in transverse myelitis: a responsive protocol

Venous thromboembolism prophylaxis for the medical patient: where do we stand?

Decubitus ulcers: pathophysiology and primary prevention

Predictors of life satisfaction: a spinal cord injury cohort study

Who wants to walk? Preferences for recovery after SCI: a longitudinal and cross-sectional study

Neurophysiology of gait disorders: present and future applications

Clinical factors that affect walking level and performance in chronic spinal cord lesion patients. Spine (Phila Pa

Functional community ambulation requirements in incomplete spinal cord injured subjects

Walking ability at discharge from inpatient rehabilitation in a cohort of non-traumatic spinal cord injury patients

Functional treatments in multiple sclerosis

Combined exercise training reduces IFN-g and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis

Levetiracetam for phasic spasticity in multiple sclerosis

Bone adaptation to altered loading after spinal cord injury: a study of bone and muscle strength

Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings

Tranverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen

Review of periodic limb movement and restless leg syndrome

Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations

Non-traumatic spinal cord lesions: epidemiology, complications, neurological and functional outcome of rehabilitation

Transverse myelitis in children: long-term urological outcomes

Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis

Symptomatic management in multiple sclerosis

A UK consensus on the management of the bladder in multiple sclerosis

Gastrointestinal involvement in spinal cord injury: a clinical perspective

Gastroparesis in multiple sclerosis

Gastroparesis secondary to a demyelinating disease: a case series

An unusual cause of gastroparesis: demyelinating disease of the medulla

Gastroparesis with multiple sclerosis

Pathophysiology and management of bowel dysfunction in multiple sclerosis

Long-term outcome and safety of transanal irrigation for constipation and fecal incontinence

Sexuality and reproductive health in adults with spinal cord injury: a clinical practice guideline for health-care professionals

Sexuality in patients with spinal cord injuries due to attempted suicide

Sexual rehabilitation of women with a spinal cord injury

Sexual function in spinal cord injury men. Assessing sexual capability

Posttraumatic erectile potential of spinal cord injured men: How physiologic recordings supplement subjective reports

International standards to document remaining autonomic function after spinal cord injury

The sexual needs of the injured spinal cord patient

Erectile dysfunction is the main determinant of psychological distress in men with spinal cord injury

Long-term effects of spinal cord injury on sexual function in men: implications for neuroplasticity

Sexual rehabilitation in women with spinal cord injury: a critical review of the literature

Female sexual dysfunction and hormonal status in spinal cord injured (SCI) patients

Ejaculatory dysfunction in spinal cord injury is suggestive of dyssynergic ejaculation

Women's sexual functioning and sex life after spinal cord injury

Assessment of autonomic dysfunction following spinal cord injury: rationale for additions to International Standards for Neurological Assessment

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology

Orthostatic hypotension in the first month following acute spinal cord injury

Sympathetic vasoconstrictor responses in multiple sclerosis with thermo-regulatory dysfunction

Thermoregulation in multiple sclerosis

Autonomic dysreflexia in acute spinal cord injury: an under-recognized clinical entity

A systematic review of the management of autonomic dysreflexia after spinal cord injury

Autonomic dysreflexia

Autonomic dysreflexia and myocardial ischemia

Reversible posterior leukoencephalopathy in a patient with autonomic dysreflexia: a case report

Autonomic dysreflexia and sudden death in people with traumatic spinal cord injury

Sacral insufficiency stress fracture as etiology of positional autonomic dysreflexia: case report

Cardiovascular responses to vibrostimulation for sperm retrieval in men with spinal cord injury

Clinical observations in vibratory stimulation of the penis of men with spinal cord injury

Rehabilitation medicine: 1. Autonomic dysreflexia

Pain and rehabilitation after spinal cord injury: the case of sensory spasticity?

Current management of pain associated with multiple sclerosis

Neurogenic pruritus: a case of pruritus induced by transverse myelitis

Bone mineral content of the lumbar spine and lower extremities years after spinal cord lesion

Longitudinal study of bone turnover after acute spinal cord injury

Bone loss in spinal cord-injured patients: from physiopathology to therapy

Spinal cord injury-related bone impairment and fractures: an update on epidemiology and physiopathological mechanisms

Mineral metabolism in spinal cord injury

Influence of season, ethnicity, and chronicity on vitamin D deficiency in traumatic spinal cord injury

Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects

Vitamin D status and effect of lowdose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis

Vitamin D and multiple sclerosis

Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis

Evidence that abnormally large seasonally declines in vitamin D status may trigger SLE flare in non-African Americans

Vitamin D level: is it related to disease activity in inflammatory joint disease?

Low vitamin D levels and recurrent inflammatory spinal cord disease

Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women

Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes

Immunomodulatory effects of vitamin D in multiple sclerosis

Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response

Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?

Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health

Effect of chronic anticonvulsant therapy on serum 25-hydroxycholecalciferol levels in adults

Critique of the considerations for establishing the tolerable upper intake for vitamin D: critical need for revision upwards

Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol

Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2

Prospective study of predictors of vitamin D status and cancer incidence and mortality in men

Vitamin D3 from sunlight may improve the prognosis of breast, colon, and prostate cancer (Norway)

Low serum calcidiol concentration in older adults with reduced muscular function

Vitamin D status, trunk muscle strength, body sway, falls, and fractures among 237 postmenopausal women with osteoporosis

Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain

Major depression in multiple sclerosis: a population-based perspective

Treatment of depression improves adherence to interferon B-1b therapy for multiple sclerosis

Nervous system involvement in ankylosing spondylitis

Transverse myelitis in a patient with longstanding ankylosing spondylitis

Combination of transverse myelitis and arachnoiditis in cauda equina syndrome of long-standing ankylosing spondylitis: MRI features and its role in clinical management

Acute transverse myelitis in psoriatic arthritis

Transverse myelitis in mixed connective tissue disease

Transverse myelitis in mixed connective tissue disease. Case report

Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis

Transverse myelopathy complicating mixed connective tissue disease. Case report

Transverse myelopathy, a rare complication of mixed connective tissue disease: comparison with SLE related transverse myelopathy

Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease-a case report and a review of literature

Transverse myelitis in systemic sclerosis

Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis

Transverse myelopathy in progressive systemic sclerosis

Neurologic manifestations of progressive systemic sclerosis

Transverse myelitis as the presentation of Jo-1 antibody syndrome (myositis and fibrosing alveolitis) in long-standing ulcerative colitis

Acute transverse myelitis and primary urticarial vasculitis

Clinical and laboratory features of myelitis patients with anti-neutrophil cytoplasmic antibodies

Systemic pANCA-associated vasculitis with central nervous involvement causing recurrent myelitis: case report

Neurological symptoms in patients with biopsy proven celiac disease

Thymic hyperplasia in a patient with recurrent transverse myelitis with clinical resolution after thymectomy

Autoimmune hemolytic anemia following T-cell-depleted allogeneic bone marrow transplantation

An immunological syndrome featuring transverse myelitis, Evans syndrome and pulmonary infiltrates after unrelated bone marrow transplant in a patient with severe aplastic anemia

Acute transverse myelitis and autoimmune pancytopenia after unrelated hematopoietic cell transplantation

Common variable immunodeficiencyassociated myelitis: report of treatment with infliximab

Primary hypogammaglobulinemia: a survey of clinical manifestations and complications

Successful immunosuppressive treatment and long-term follow-up of anti-Ri-associated paraneoplastic myelitis

Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments

Amphiphysin autoimmunity: paraneoplastic accompaniments

Stiff leg syndrome and myelitis with antiamphiphysin antibodies: a common physiopathology?

Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association

Paraneoplastic encephalitis, psychiatric symptoms and hypoventilation in ovarian teratoma

NMDA receptor encephalitis mimicking seronegative neuromyelitis optica

N-Methyl-D-aspartate receptor antibody encephalitis associated with myelitis

Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report

Etanercept induced multiple sclerosis and transverse myelitis

Transverse myelitis secondary to sulfasalazine

Acute transverse myelopathy probably related to intravenous gemcitabine plus cisplatin

Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy

Cytarabine and neurologic toxicity

Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type

Acute neurological toxicity of intrathecal cytosine arabinoside: a case report

Spinal analgesia and cauda equina lesions

An analysis of the complications of extradural and caudal block

Paraplegia following general anaesthesia

Neurological complications following general anaesthesia. Three cases of major paralysis

A postoperative neurological problem

Transverse myelitis following general anaesthesia

Transverse myelitis following general and epidural anaesthesia in a paediatric patient

Transverse myelitis associated with heroin addiction

Acute myelopathy in association with heroin addiction

Acute myelopathy following intranasal insufflation of heroin: a case report

Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF

Benzene poisoning as a possible cause of transverse myelitis

Transverse myelitis and paralysis from a brown recluse spider bite

Comparison of clinical and electrodiagnostic features in B12 deficiency neurological syndromes with and without antiparietal cell antibodies

Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis

Case 87: subacute combined degeneration

Anchor"-shaped bright posterior column in a patient with vitamin B12 deficiency myelopathy

Spinal MRI in progressive myeloneuropathy associated with vitamin E deficiency

Vitamin E-deficient spinocerebellar syndrome due to intestinal lymphangiectasia

Progressive neuropathologic lesions in vitamin E deficient rhesus monkeys

Combined optic neuropathy and myelopathy secondary to copper deficiency

Acute and bilateral blindness due to optic neuropathy associated with copper deficiency

Denture cream: an unusual source of excess zinc leading to hypocupremia and neurologic disease

Copper deficiency myelopathy (human swayback)

Copper deficiency myelopathy

Pseudo-Guillain-Barre syndrome due to "whippet"-induced myeloneuropathy

Subacute combined degeneration of the spinal cord caused by nitrous oxide anaesthesia

Nitrous oxide use in first-year students at Auckland University

Neurologic diseases associated with use of plant components with toxic potential

Primary central nervous system lymphoma

Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI detectability

Primary intramedullary spinal cord lymphoma

The neurological masquerade of intravascular lymphomatosis

Intravascular lymphoma presenting as progressive paraparesis

A case of intravascular B-cell lymphoma presenting as myelopathy and diagnosed postmortem

Intravascular lymphoma presenting as a longitudinally-extensive myelitis: diagnostic challenges and etiologic clues

Epidemiology of cauda equina and conus medullaris lesions

Intravascular lymphomatosis presenting with a conus medullaris syndrome mimicking disseminated encephalomyelitis

Post-radiotherapy myelitis observed in an AIDS patient with a meningioma: case report and review of the literature

Radiation myelopathy

Increased vulnerability of the spinal cord to radiation or intrathecal chemotherapy during adolescence: a report from the Children's Oncology Group

Radiation myelopathy in overirradiated patients: MR imaging findings

Physical rehabilitation as an agent for recovery after spinal cord injury

Lower extremity orthotic management for the spinal-cord-injured client

Neurotherapeutic and neuroprosthetic effects of implanted functional electrical stimulation for ambulation after incomplete spinal cord injury

Does functional electrical stimulation for foot drop strengthen corticospinal connections?

Effectiveness of robot-assisted gait training in persons with spinal cord injury: a systematic review

Neuromuscular stimulation therapy after incomplete spinal cord injury promotes recovery of interlimb coordination during locomotion

A phase 3 trial of extended release oral dalframpridine in multiple sclerosis

Botulinum injections for the treatment of bladder symptoms of multiple sclerosis

Antimicrobial prophylaxis for urinary tract infection in persons with spinal cord dysfunction

Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder

Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis

A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis

The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder

Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study

Treatment of symptoms in multiple sclerosis

Management of bowel dysfunction in people with multiple sclerosis

Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis

Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction

Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature

Erectile function and male reproduction in men with spinal cord injury: a review

Effects of vibratory stimulation on sexual response in women with spinal cord injury

A new non-pharmacological vacuum therapy for female sexual dysfunction

EFNS guidelines on the diagnosis and management of orthostatic hypotension

Electrically induced and voluntary activation of physiologic muscle pump: a comparison between spinal cord-injured and able-bodied individuals

Cardiovascular responses to an orthostatic challenge and electrical-stimulation-induced leg muscle contractions in individuals with paraplegia

Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group

Pyridostigmine treatment trial in neurogenic orthostatic hypotension

L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure

Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury

Severe hypertension in patients with high spinal cord lesions undergoing electro-ejaculation-management with prostaglandin E2